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Mouse models are essential tools for biomedical research, allowing researchers to investigate 
gene function and model human diseases. The mouse genome can be manipulated to ablate 
(“knockout”) gene function, create targeted point mutations or insert transgenes or small 
epitope tags. Previous gene targeting methods for creating these modifications were slow and 
inefficient. The arrival of CRISPR/Cas9 genome editing technology has revolutionised the 
production of genetically modified mice as it is easy to use, efficient and cost-effective. The 
research comprised in this PhD thesis explores the use of genetically modified mice to better 
understand human diseases, as well as developing new technologies for mouse genome 
editing. 
The first manuscript describes a phenotypic investigation of the transgenic Prrt2 knockout 
(Prrt2 KO) mouse. In humans, mutations in PRRT2 cause an infantile epilepsy syndrome (benign 
familial infantile epilepsy; BFIE) and a movement disorder in adolescence (paroxysmal 
kinesigenic dyskinesia; PKD). We identifed a spontaneous paroxysmal phenotype in Prrt2 KO 
animals, as well as premature death in HET and KO mice. Behavioural tests also revealed 
learning deficits and gait abnormalities in KO mice that may reflect phenotypes in homozygous 
patients, confirming the utility of this model for investigating PRRT2-related disorders.  
The second manuscript examines variants of the Streptococcus pyogenes Cas9 endonuclease 
(WT SpCas9) commonly used for CRISPR genome editing. Numerous Cas9 variants have 
recently been characterised, each recognising different PAM sequences. Most of these variants 




endonuclease variants (SpCas9 VQR, SpCas9 VRER, SaCas9 KKH and AsCpf1) for their ability to 
edit the mouse genome via mouse zygote injection, with the aim of expanding PAM targeting 
options. We showed that all variants are able to mutate the mouse genome, albeit with 
different efficiencies.  We also highlighted the propensity of SaCas9 KKH to generate 
heterozygotes or mosaic offspring in which at least one allele remains unmodified. When 
editing using a ssDNA oligonucleotide repair template, SaCas9 KKH consistently left a wild type 
allele in correctly targeted offspring, whilst WT SpCas9 frequently mutated the other allele. 
This characteristic could be beneficial when targeting genes in which nullizygous mutations 
cause embryonic lethality, as the high efficiency of WT SpCas9 commonly prevents the 
production of viable offspring. 
With CRISPR/Cas9 technology, it has become quick and efficient to tag endogenous proteins 
with small epitope tags. The third manuscript in this thesis compares a series of commercially 
available antibodies for their efficacy to detect epitope tags on Pcdh19 HA-FLAG expression in 
mouse brain tissue. This model was generated within the laboratory to allow specific staining 
of PCDH19 for investigating protocadherin 19 girls clustering epilepsy. Of the 8 antibodies 
tested, only two (one HA and one FLAG) were specific for PCDH19. This data will provide 
guidance for researchers designing similar studies, preventing extensive optimisation of 
immunofluorescent staining.  
Together, the data presented in this thesis demonstrate the versatility and importance of 
mouse models for the study of gene function and neurological disease. This research provides 
more options for producing genetically modified mice and streamlines the downstream 
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Epilepsy is a heterogeneous disorder characterised by recurring seizures. It affects around 3% 
of the population at some point in life and due to its unpredictable nature, can be extremely 
deleterious to quality of life 7. Clinically, epileptic seizures can be categorised into two broad 
classes: focal and nonfocal epilepsy. Focal epilepsies originate from one cerebral hemisphere, 
whilst nonfocal is generalized, involving both hemispheres 8.  
Whilst some causes for epilepsy have been known for decades (e.g. stroke, trauma), many 
were considered ‘idiopathic’, indicating an unknown cause. It is only more recently that the 
genetic causes have come to the fore, revealing a number of epilepsies with single-gene 
causes, as well as those with more complex inheritance involving multiple genetic loci 9. It is 
likely that many of these epilepsies are a result of an imbalance in excitatory and inhibitory 
neurotransmission within neural networks of the brain. In line with this, many monogenic 
epilepsies are caused by mutations in genes encoding ion channels (channelopathies), whilst 
others involve dysfunction in regulators of neurotransmission 10, 11. An emerging example of a 
single-gene epilepsy is benign familial infantile epilepsy (BFIE), which is caused by mutations in 






1.2 Mutations in PRRT2 cause PKD, BFIE and ICCA  
Benign familial infantile epilepsy (BFIE) is an autosomal dominant epilepsy disorder that affects 
infants with an onset between 3-12 months of age. Seizures are usually afebrile and partial 
complex (beginning in one region of the brain and causing loss of consciousness) or generalised 
tonic-clonic in nature (affecting the entire brain and causing stiffening and uncontrolled 
jerking) often occurring in clusters, although some phenotypic variability exists. The disorder 
tends to offset by around 2 years of age and affected infants have normal neurological 
development thereafter 12-14. 
Paroxysmal kinesigenic dyskinesia (PKD; also known as paroxysmal kinesigenic 
choreoathetosis) is an episodic movement disorder that affects patients in late-childhood or 
adolescence, becoming less severe with age 12. The disorder is characterised by brief attacks (≈ 
1 min) of dystonic (twisting or abnormal) movements and/or choreoathetosis (the combination 
of contractions and twisting/writhing) that are brought on by sudden voluntary movements 
such as standing up from a resting position. Patients do not feel pain or lose consciousness 
during attacks. Inheritance is autosomal dominant with incomplete penetrance, though 
sporadic cases have also been identified 15, 16. PKD falls within a group of three paroxysmal 
movement disorders that can be discriminated by the stimuli that give rise to the attacks. The 
other included disorders are paroxysmal exercise-induced dyskinesia (PED) which is brought on 
by exercise and paroxysmal non-kinesigenic dyskinesia (PNKD) that can be induced by stress, 
caffeine or alcohol.  
Infantile convulsions and choreoathetosis syndrome (ICCA; also infantile convulsions with PKD; 




and PKD. Previously, linkage analyses showed that all three disorders link to the same region 
on chromosome 16, a region including PRRT2 17, 18. 
Whilst linkage to this region was first identified in 1997 17 and genes within it screened for 
mutations, it was not until 2011 that Chen et al. identified heterozygous mutations in proline 
rich transmembrane protein 2 (PRRT2) in eight Chinese families with PKD 16. Following this 
discovery, the gene was shown to be causative of both BFIE and ICCA across many families 
with varying genetic backgrounds 13, 19, 20. A number of other episodic disorders have also been 
associated with PRRT2 mutations including hemiplegic migraine (HM) and other forms of 
paroxysmal dyskinesia (PED, PNKD) 21, 22. Homozygous mutations in PRRT2 have been observed 
in two consanguineous families and in both cases resulted in severe intellectual disability. 
Whilst one family was described as non-syndromic, two homozygous individuals from the 
other experienced PKD, episodic ataxia (EA) and childhood absence epilepsy (CAE) 23, 24.  
More than 50 different mutations have been identified within PRRT2 to date, including 
frameshift, missense, nonsense and splice site mutations, as well as 3 large deletions that span 
up to 30 genes, including PRRT2 1, 12, 13. A breakdown of mutations, their type and location in 
the gene is shown in Figure 1.1a. There is no apparent genotype-phenotype correlation to 
explain the different disease outcomes, indicating that other environmental or genetic factors 










Figure 1.1: Mutations in proline rich transmembrane protein 2 (PRRT2) cause paroxysmal 
disorders. a) PRRT2 gene structure with disease causing mutations annotated. 
Nonsense/frameshift mutations are detailed above with missense mutations below. 
Relevant domains highlighted including proline rich domain (PRD), membrane bound 
domains (M1a, M1b & M2) and cytoplasmic loop (CYT). b) Simple schematic of PRRT2 
protein structure and placement on the intracellular side of the membrane. Proline rich 





1.3 PRRT2 structure  
Before its implication in disease, PRRT2 was a largely uncharacterised gene. It consists of four 
exons, which encode a polypeptide that is 340 amino acids long, containing two putative 
transmembrane domains near the C-terminus and what was thought to be an extracellularly 
located N-terminus 16. However, using live immunolabelling, electron microscopy and 
computational modelling, recent studies have revealed that PRRT2 has an intracellular N-
terminus and a short extracellular region at the C-terminus 25. It is classified as a Type II 
transmembrane protein, with only a single transmembrane domain. The second hydrophobic 
domain associates with the intracellular membrane surface (Figure 1.1b).  
Most mutations are predicted to lead to truncation of PRRT2, thereby causing a loss of protein 
function. The missense mutations identified mostly cluster around the C-terminal end of the 
protein which contains the hydrophobic domains (Figure 1a). These domains are highly 
conserved (~90% similarity with other mammals) and the entire gene shares 80-90% similarity 
with most mammals 20. As most PRRT2 mutations discovered thus far affect one or both of 
these highly conserved hydrophobic domains, there is strong evidence to support their 





1.4 Neuronal function of PRRT2 
Analysis of Prrt2 expression has provided clues for its role in brain-related disorders. In mice, it 
is largely confined to the CNS, with highest expression in the cortex, basal ganglia and 
cerebellum 16, 19, 20, 26, 27. These regions of high Prrt2 expression are consistent in the human 
adult brain 1, 14. Temporally, levels of PRRT2 are low during early murine development (before 
embryonic day 16) and peak at postnatal day 14. Expression levels in the mouse brain are 
lower and persist throughout adulthood 16, 26.  
Subcellular localisation has been investigated by multiple groups, beginning with colocalisation 
studies in mouse primary neurons, showing an overlap between overexpressed PRRT2 and 
synapse protein synapsin 1 at synaptic puncta 20. Ultrafractionation of mouse brain tissue has 
further confirmed its synaptic localisation, with high levels in pre-synaptic fractions and only 
low levels in post-synaptic densities 26, 28.  
Consistent with this, coimmunoprecipitation and pulldown analyses have revealed numerous 
interactions with synapse proteins, suggesting a functional role for PRRT2 at the synapse. The 
first interaction described was with SNAP25 (synaptosomal associated protein of 25 kDa), a 
component of the SNARE complex, responsible for bridging synaptic vesicles to the membrane 
during exocytosis 20, 29. Furthermore, Valente et al. described interactions with another SNARE 
protein VAMP2/synaptobrevin-2 and Ca2+ sensors synaptotagmin 1 and 2 (Syt 1 & 2), whilst 
Tan et al. observed PRRT2 interaction with Syntaxin 1A 26, 27. When an action potential occurs 
along a neuron, the result is an influx of calcium (Ca2+) to the presynaptic terminal. This is 
sensed by Syt1/2 on the vesicle surface, which then bind the SNARE proteins. The SNARE 




synaptobrevin, which then catalyse vesicle fusion to the membrane and neurotransmitter 
release into the synapse (See Figure 1.2a) 1, 30. 
Knockdown of Prrt2 in vitro and in vivo results in defects in synapse structure and function. 
Prrt2 shRNA silencing in primary cultured neurons results in a decrease in synaptic density, and 
knockdown in vivo causes decreased dendritic spine density, suggesting a role in development 
26, 28. Further to this, knockdown of Prrt2 in the developing mouse brain also results in delays in 
neuronal migration, though by postnatal day 1 (P1) knockdown cells reach the cortical plate as 
normal 28. Electrophysiological examination of the effects of Prrt2 knockdown in vitro revealed 
decreased synchronous release, concomitant with only subtle differences in asynchronous 
release (Ca2+ independent). Prrt2 silenced neurons are also insensitive to increases in 
extracellular Ca2+ 26. This, along with its association with Syt1/2, indicates a role for PRRT2 in 
pairing Ca2+ sensing machinery with the SNARE complex proteins to facilitate synchronous 
exocytosis of synaptic vesicles (Figure 1.2b) 1. 
A recent in vitro study using reconstituted protein assays showed that PRRT2 can also inhibit 
SNARE-mediated vesicle fusion31. The expression of wild type Prrt2 in PC12 cells inhibited 
fusion events through weak interactions with synaptic SNARE proteins. Furthermore, a non-
synaptic role for PRRT2 was described by Fruscione et al., through studies on patient neurons 
derived from iPS cells and Prrt2 KO mouse neurons 32. Researchers demonstrated that PRRT2 
inhibits Na+ influx by directly interacting and limiting surface expression of sodium channels 
Nav1.2 and Nav1.6. This results in higher Na+ currents in homozygous mutant patient neurons 







Figure 1.2: Key steps for synaptic vesicle exocytosis. a) Diagram of the processes 
involved in neurotransmitter exocytosis including key proteins and the proposed 
involvement of PRRT2. b) A mechanistic model for the role of PRRT2 in responding to 





1.5 Prrt2  KO mice 
As human disease mutations in PRRT2 are expected to lead to a loss of protein function, a Prrt2 
knockout mouse model (Prrt2 KO) has the potential to be a useful system for investigating the 
underlying mechanisms of the related diseases. Recently, two groups have investigated mice 
with mutations in Prrt2.  
The first, described by Michetti et al., was a Prrt2 ‘knockout first’ (Prrt2 KO) mouse with a 
splice acceptor and lacZ transgene inserted before the first coding exon, abolishing expression 
of the protein and allowing visualisation of tissue localisation 33. LacZ staining in the Prrt2 KO 
mouse indicated expression in concentrated regions including the cerebellum, hippocampus 
and cerebral cortex. Prrt2 KO pups showed unusual spontaneous motor behaviours such as 
bouncing and backward walking during development, some of which persisted into adulthood.  
Adult mice heterozygous (HET) or homozygous (KO) for the knockout allele were 
indistinguishable from wild type (WT) when subjected to locomotor, footprint/gait and 
accelerating rotarod testing, suggesting a normal motor/coordination profile despite motor 
paroxysms. Given the intellectual disability seen in patients, cognitive testing on these mice 
was carried out (novel object recognition and cued/contextual fear conditioning test) though 
no differences between genotypes were observed. Interestingly, whilst Prrt2 KO and HET mice 
did not experience spontaneous seizures, KO animals (and not WT) could be triggered into wild 
running episodes following audiogenic stimulation. EEG activity was unaltered during these 
attacks indicating a motor paroxysm rather than a seizure. When probed for seizure 
susceptibility using proconvulsant pentylenetetrazol (PTZ), KO animals displayed significantly 




A second group described a series of Prrt2 mouse models, seeking to elucidate functional 
regions, as well as establish a model for the human diseases 27. The most extensively 
characterised mouse in this study (Prrt2STOP) mimics the common disease-causing mutation 
c649dupC (occurs in 80% of patients) by inserting two stop codons at the corresponding site in 
mouse Prrt2 causing loss of function. Electron microscopy analysis on cerebellar samples from 
these mice reveal no differences in synaptic density or active zone length, though more 
synaptic vesicles were docked at the membrane. Prrt2STOP mice showed normal gait, muscle 
strength and locomotion but displayed deficits in the beam walking and rotarod tests which 
test motor coordination and balance. Rotarod testing on the Prrt2 KO mouse showed no 
difference between genotypes, making this a point of difference between the two models. The 
Michetti et al model is maintained on a C57Bl/6N substrain whilst the Tan et al model is 
maintained on C57Bl/6J. Sub-strain genomic and phenotypic differences may explain different 
performance on these tests34. 
Spontaneous attacks of dyskinesia were observed at low frequency in Prrt2STOP mice but could 
not be induced by sudden movement or stimulation with substances such as caffeine, ethanol 
or cocaine. Kindling stimulation with repeated administration of sub-convulsive electrical 
impulses resulted in seizures followed closely by dyskinetic attacks in Prrt2STOP homozygotes 
and heterozygotes but not wild type littermates. When injected with PTZ or exposed to heat, 
Prrt2STOP mice had significantly shorter latency to seizure than wild type and experienced 
attacks of dyskinesia following these seizures. Again, the discrepancy in PTZ results between 
Prrt2 STOP and Prrt2 KO mice could be attributed to differences in the C57Bl/6 substrain. 
Optogenetic stimulation of neurons in the cerebellum of Prrt2STOP homozygous mice using 




cerebellum in Prrt2 mouse phenotype. When Prrt2 was knocked out only in granule cells of the 
cerebellum (using GluN2C-Cre), mice showed similar behavioural phenotypes to Prrt2STOP 
animals. Conversely, mice with conditional knockout in the forebrain only (using CaMKIIa-Cre) 
did not experience heat induced seizures/dyskinetic attacks. Together these data indicate that 






1.6 Mouse models for disease 
The utility of genetically manipulated mice as tools for biomedical research, particularly when 
investigating complex neurological disorders such as epilepsy, is demonstrated by the 
aforementioned Prrt2 mouse studies. In general, mouse KO models provide an in vivo system 
for understanding gene or protein function, as well as investigating the underlying mechanisms 
of disease and can be used to perform rigorously controlled experiments that are not possible 
on human patients. Mice and humans share 99% of their genes and have extensive 
physiological similarities, allowing researchers to model human pathologies 35. In addition to 
the Prrt2 studies, several other epilepsy genes have been successfully studied using mouse 
models 36-38.  
Compared to other mammals, mice are also relatively cheap to house and have fast 
reproduction times, with a total lifespan of around two years. The mouse genome is easily 
manipulated to mimic human disease mutations or to insert short DNA sequences and longer 
gene or reporter constructs. These DNA modifications have historically been achieved through 
a method called gene targeting. More recently however, genome editing techniques have been 
characterised and allow direct injection of reagents into the mouse zygote for one-step 





1.7 Gene targeting for transgenic mice  
Gene targeting utilises the homologous recombination process inherent to mammalian cells to 
mediate the transfer of exogenous DNA into the genome. To generate mutant mice using this 
method, researchers deliver a targeting vector containing the donor DNA sequence along with 
long homology arms into mouse embryonic stem cells (ES cells). The genetically modified ES 
cells are implanted into the early mouse blastocyst, before transfer into a pseudopregnant 
female. Resulting founders are chimeric for the desired mutation and are then bred with wild 
type mice to create heterozygotes for starting a colony.  
Since its development in the 1980’s, this process has become an important tool for 
investigating gene function, particularly by knocking out a gene of interest 39. Indeed, the 
International Knockout Mouse Consortium (IKMC) aims to create and phenotype knockout 
mouse lines for all 20,000 known mouse genes and make them publically available to 
researchers 40. Many of these mice have been created using a ‘knockout first’ strategy that 
causes knockout of the gene but is reversible via the Flp-FRT recombination system. An 
important feature of this allele type is the insertion of the engrailed splice acceptor followed 
by a promoterless lacZ gene to facilitate expression of β-galactosidase in place of the gene of 
interest. Additionally, LoxP sites flank a coding exon to allow conditional knockout of the gene 
using a mouse with Cre-recombinase under a tissue-specific promoter. The Prrt2 KO mouse 
discussed above and used in the study reported in Chapter 2 is an example of a gene targeting 
mouse created through this consortium 33.  
Whilst the process of gene targeting has allowed researchers to investigate gene function and 




finding that double stranded breaks (DSBs) in DNA can increase the efficiency of gene 
targeting/ donor DNA integration opened up the field of mouse genome editing dramatically 2, 
41, 42. Meganucleases, zinc finger nucleases (ZFN), transcription activator-like effector nuclease 
(TALEN) and clustered regularly interspaced short palindromic repeats (CRISPR) are all 
techniques that use this principal to bring about DNA modification. These technologies, in 
particular CRISPR/Cas9, have facilitated the rapid and efficient production of mice, overcoming 
many of the issues (Figure 1.3). They will be introduced here and form the basis of the study 









Figure 1.3: CRISPR/Cas9 genome editing technique compared to gene targeting for 
producing genetically modified mice. Mutations in mice are generated rapidly (less than 6 





1.8 Genome editing techniques 
Meganucleases are naturally occurring endonucleases that are able to recognise 14-40bp 
stretches of DNA and create DSBs. A major difficulty with their use for genome editing, 
however is that their specific recognition sequence is unlikely to be present at the desired 
target locus, requiring incorporation of the sequence prior to genome editing. ZFN and TALEN 
technology overcome this issue as they can be tailored to target virtually any sequence in the 
genome (Figure 1.4). Both are engineered proteins consisting of naturally occurring DNA-
binding domains (ZF or TALE) fused to the non-specific FokI nuclease for target cleavage. For 
ZFN, each DNA binding domain recognises 3 nucleotides, whilst each TALE domain binds a 
single nucleotide. These can be arranged in a modular fashion to recognise a target sequence. 
Since FokI requires dimerization to induce double stranded breaks, pairs of these proteins are 
used on opposite DNA strands for its use in genome editing 43, 44. Both techniques have been 
used effectively for editing of the mouse genome 45-47. However, each new genomic target 
requires the design, synthesis and validation of new nucleases. As a result, the difficulties and 
expenses associated have prevented their wider use 2. Many of these issues were addressed 
with the discovery that the bacterial CRISPR/Cas9 system could be adapted for use in genome 
editing.  
Target specificity for CRISPR/Cas9 nucleases is provided by short guide RNAs that form 
complementary base-pairing with genomic DNA. The nuclease therefore, is the same for every 
experiment, with the RNA guide being easily designed and produced at little cost. A key 
advantage of gene editing techniques over the historical gene targeting in mice is that they 




reagents, the zygotes are transferred to a pseudopregnant female. Founder pups resulting 
from these kinds of experiments can be genotyped for the desired mutation and have a high 













Figure 1.4: Genome editing technologies: meganuclease, zinc-finger nuclease (ZFN), 
transcription activator-like effector nuclease (TALEN) and CRISPR/Cas9. Meganucleases 
recognise long (14-40bp) specific sequences of DNA to induce a double-stranded break 
(indicated by red arrows). ZFN and TALENs are modular proteins that specifically bind 
DNA and guide non-specific Fok1 nuclease to genomic sites. CRISPR/Cas9 is an 





1.9 CRISPR/Cas9 technology 
CRISPR systems occur naturally in prokaryotes as part of the antiviral adaptive immune 
system48. The CRISPR system most commonly used comes from Streptococcus pyogenes 
(SpCas9). After insertion of exogenous DNA, the bacteria incorporate small segments of this 
DNA into a CRISPR locus. The CRISPR locus is transcribed into pre-crRNA that is processed into 
crRNAs. These crRNAs complex with another short RNA called the transactivating RNA 
(tracrRNA), as well as the Cas9 endonuclease. This complex is guided to the foreign DNA by the 
crRNA and Cas9 mediates a double-stranded break (DSB) in the DNA, facilitating its 
degradation 49. Importantly, the Cas9 requires a specific sequence adjacent to the target region 
(known as the proto-spacer adjacent motif; PAM). In the case of SpCas9, an NGG PAM is 
recognised. The PAM sequence is not incorporated into the CRISPR locus, providing a point of 
difference to distinguish the bacterial cells’ own DNA from the exogenous DNA with sequence 
homology, preventing self-targeting 50.  
The CRISPR/Cas9 system from SpCas9 was the first to be characterised for genome editing, 
triggered by the finding that it could cleave DNA in vitro51. Shortly thereafter, two groups 
described genome editing in mammalian cell lines 52, 53. For simplicity, the crRNA and tracrRNA 
components were combined, resulting in a single guide RNA (sgRNA) that complexes with Cas9 
for target cleavage. This sgRNA is ~100bp in length with only around 20bp of target-specific 
sequence, making it simple and cheap to produce in the laboratory. The Cas9-RNA complex 
begins by randomly colliding with the DNA, binding where an NGG is present and rapidly 
dissociating from non-PAM sites. When a PAM site is bound, the Cas9-RNA complex tests the 




sequence complementarity has been achieved, DNA cleavage is carried out by two separate 
nuclease domains: RuvC and HNH. These domains nick one strand of DNA each, resulting in a 
blunt DSB located three nucleotides upstream of the PAM (Figure 1.5) 54, 55. As discussed later 
in this chapter, once a DSB has been made in the DNA, it is repaired by the cells’ endogenous 








Figure 1.5: CRISPR/Cas9 genome editing technology. The Cas9 protein creates a double-
stranded break (DSB) three base pairs upstream of an NGG protospacer adjacent motif 
(PAM). Target specificity is provided by complexing with the crRNA and tracrRNA, which can 





1.10 Variations of the CRISPR/Cas9 system 
One of the limitations of SpCas9 is the requirement for an NGG PAM to be directly adjacent to 
the desired cleavage site. NGG PAM sites are found every 8-12bp on average. This does not 
pose a restraint for most CRISPR applications, however when creating a DSB with the aim to 
precisely insert a sequence using the homology directed repair pathway, more targeting 
flexibility is often desired. An inverse relationship between mutation incorporation rate and 
distance from DSB has been described, highlighting a need for more PAM recognition options 
56. Variations of the CRISPR/Cas9 system have been developed for genome editing and 
contribute to the ever-expanding toolkit of RNA-guided endonucleases(Figure 1.6) 2. 
 A series of Cas9 orthologues have been characterised, many of which recognise different PAM 
sequences (summarised in Figure 1.6). These include Francisella novicida Cas9 (FnCas9, NGG 
PAM), Staphylococcus aureus Cas9 (SaCas9, NNGRRT PAM), Neisseria meningitidis Cas9 
(NmCas9, NNNNGATT PAM) and Streptococcus thermophiles Cas9 (St1Cas9/St3Cas9, 
NNAGAAW/NGGNG PAM) 57-60. Additionally, Zetsche et al. characterised a class 2 CRISPR 
endonuclease called Cpf1 from both Acidaminococcus sp. BV3L6 and Lachnospiraceae 
bacterium ND2006 that recognises a TTTN PAM 5’ of its target sequence and creates a 
staggered cut in the DNA distal to its PAM 61.  
Variants with altered PAM recognition have also been engineered 2. Kleinstiver et al. used 
structural information and a bacterial selection system to create the VQR, EQR and VRER 
variants. VQR SpCas9 contains mutations in three residues (D1135V/R1335Q/T1337R) and 
recognises a NGAN PAM sequence. The EQR SpCas9 variant, similar to VQR, contains a 




NGAG PAM sequence. The third SpCas9 variant described in this study is VRER SpCas9 and 
contains four mutated residues (D1135V/G1218R/R1335E/T1337R), recognising NGCG PAMs 
58. The same group also produced an engineered form of SaCas9 with a less restrictive PAM 
recognition 62. The wild type form of SaCas9 recognises an NNGRRT PAM sequence, however 
molecular evolution of the PAM-interacting domain resulted in a variant with three mutated 
residues (E782K/N968K/R1015H; SaCas9 KKH) which is highly active at NNNRRT PAM sites. 
FnCas9 (NGG PAM) was also engineered, resulting in a variant recognising a more flexible YG 
PAM through mutations in three residues (E1369R/E1449H/R1556A; RHA FnCas9) 57. 
Together, the Cas9/Cpf1 endonucleases from different species and engineered variants expand 
the targetable regions of the genome, providing more flexibility for the design of gRNAs to 
specific loci. FnCas9, FnCas9 RHA, As/LbCpf1 and SaCas9 have been tested via mouse zygote 
injection and are able to cleave and produce mutations, though many species/engineered Cas9 








Figure 1.6: Naturally occurring and engineered variants of the CRISPR system. 
Protospacer adjacent motif (PAM) requirement highlighted in blue with cut sites indicated 






1.11 CRISPR/Cas9 target specificity  
Despite the efficiency and flexibility of the CRISPR/Cas system, a major concern for the 
technology is off-target activity. This occurs at unintended loci with sequence similarity to the 
target gene, sometimes with high frequency. Non-specific cleavage can not only confound 
experiments but is highly problematic for therapeutic applications of the technology. 
Numerous methods to reduce off-target activity have been investigated, most with the aim to 
also maintain on-target activity of the enzyme. Bioinformatics tools that assess candidate 
guides for their likely off-target sites are a useful way to reduce off-target binding. Many of 
these tools simply require the input of a short sequence of interest and can design the guide, 
as well as score it for off-target binding against a reference genome. This allows researchers to 
avoid guides that have very few mismatches to an off-target site, especially if this falls within a 
coding region of another gene. Despite best efforts to avoid potential off-targets, the issue 
cannot be completely resolved at point of gRNA design and numerous other methods have 
been described to reduce these events. 
Truncation of the guide sequence at the 5’ end to 17 or 18 nucleotides was shown to reduce 
off-target activity whilst maintaining on target efficiency 66, 67. The delivery of Cas9 protein and 
gRNA as a ribonuclear protein complex (RNPs), instead of a plasmid encoding the protein also 
helps to improve Cas9 specificity as the RNPs are able to cleave DNA immediately after delivery 
and are degraded quickly, limiting the time that the complex is active within the cell 68, 69. 
Other strategies reduce off-target activity by modification of the Cas9 protein, meaning two 
simultaneous Cas9 binding events must occur for induction of a double stranded break. One 




nickase version of Cas9 (Cas9n) that can only cut a single strand (which is easily repaired within 
the cell without mutation) 70, 71. Pairing of two gRNAs on opposite DNA strands is required for 
Cas9n to create a DSB in the DNA and result in mutation. A similar approach fuses a 
catalytically inactive Cas9 (dCas9) to a non-specific FokI nuclease that requires dimerization for 
induction of DSB 72-74. Whilst effective for reducing off-target activity, these strategies can be 
an issue given the size constraints when using viral delivery as they require two gRNAs and (in 
the case of FokI) an additional protein domain. 
A number of engineered variants of Cas9 have been described that alter non-specific binding of 
the protein to DNA. These were designed using the crystal structure of Cas9. The enhanced 
specificity eSpCas9 1.1 variant contains mutations in residues that contact the non-target 
strand of DNA (K848A/K1003A/R1060A), requiring more stringent base pairing with the target 
strand and resulting in reduced off-targets 75. Another high-fidelity variant, known as SpCas9-
HF1 alters residues that contact the target DNA strand (N497A, R661A/Q695A/Q926A) to 
reduce off-target activity 76. More recently, Jennifer Doudna’s group described a new hyper-
accurate variant (named HypaCas9) following analysis of domain movement in the eSpCas9 1.1 
and SpCas9-HF1 endonucleases 77. They found the REC3 domain to be responsible for sensing 
target accuracy before conformational changes allowing DSB induction. Analysis of clusters of 
mutations within REC3 resulted in the engineering of HypaCas9 with mutations in residues 
(N692A/M694A/Q695A/H698A). This variant appears to maintain strong on-target cutting 




1.12 Mouse genome editing with CRISPR/Cas9  
The presence of a DSB, such as those elicited by CRISPR/Cas9, is extremely deleterious to the 
cell. Therefore, endogenous DNA repair systems act quickly to repair this (Figure 1.7). The most 
prominent of these is non-homologous end joining (NHEJ) which ligates broken DNA ends back 
together 78. The canonical NHEJ (cNHEJ) pathway does not require a repair template, but 
instead relies on the DNA binding factors Ku70 and Ku80, which form a heterodimer at the 
DNA ends for stability and recruit factors that process the DNA ends and facilitate rejoining 79. 
If cNHEJ is activated after DSB induction by CRISPR/Cas9, the usual outcomes are small 
deletions or insertions (indels) at the break point. This has resulted in cNHEJ being termed 
‘error prone’, however this may not be completely true; instead simply a bias as this is the 
most commonly observed outcome. It is more probable that cNHEJ results in high fidelity 
repair, however this will restore the target sequence, allowing Cas9 to re-cleave indefinitely 
until an error in repair eventually destroys the target sequence, preventing further cleavage 80.  
Other more error-prone repair mechanisms that can occur after a DSB are single strand 
annealing (SSA) and alternate end joining/microhomology-mediated end joining 
(aNHEJ/MMEJ). They differ from cNHEJ in the enzymes that mediate repair and rely on base 
pairing between short (for MMEJ) or longer (SSA) regions of homology following resection of 
the DNA. This results in deletion of the region between the homology (Figure 1.7) 81.   
Both cNHEJ and aNHEJ repair mechanisms are useful for genome editing as small indels can 
disrupt the open reading frame (ORF) of a gene, often resulting in nonsense mutations 51, 53, 70. 
In mice, harnessing cNHEJ/aNHEJ repair is the simplest and most efficient way to generate a 




ORF is likely to truncate the protein and abolish its function. Multiplexed genome editing has 
also been demonstrated in mice, allowing production of mice with mutations in multiple genes 
following a single zygote injection 84. If two DSB are introduced at the same time, a large 
deletion between the two sites can occur, allowing deletion of whole exon, gene or regulatory 
region 52, 85. To date, deletions as large as 24.4Mb have been reported in mice and up to 30Mb 
in a human cell line 86, 87.  
Another repair pathway that can be exploited for genome editing is homology directed repair 
(HDR). This pathway requires a homologous template (which under normal cellular conditions 
is usually the sister chromatid) to mediate precise repair over the DSB 6. To utilise this for 
editing the mouse genome, a single stranded DNA (ssDNA) oligo or double-stranded DNA 
(dsDNA) donor can be co-injected with the CRISPR/Cas9 reagents to provide a repair template. 
This method allows subtle alteration of the genome such as point mutations which are usually 
incorporated using ssDNA templates with 50-80bp homology flanking the donor sequence 84. 
Short DNA sequences such as LoxP sites can also be inserted using two gRNAs and two ssDNA 
donors, allowing the production of conditional alleles, though many groups have experienced 
poor efficiency with this method 3, 88.  
The CRISPR/ssDNA donor technique has also made it fast and efficient to insert a small epitope 
tag onto a protein of interest. Epitope tags overcome a common problem faced by researchers 
who lack of specific antibody for an endogenous protein. This was demonstrated by Yang et al. 
when they tagged endogenous Sox2 with a V5 tag resulting in tag insertion in 12 out of 35 




developing mouse brain with CRISPR reagents and oligo donor delivered via in utero 
electroporation 89. 
Whilst small sequences can be inserted with reasonable efficiency, the constraints of synthetic 
ssDNA production mean that longer inserts such as fluorescent reporters or genes are usually 
inserted via dsDNA templates, delivered via plasmid. These techniques have suffered low 
efficiency 88, 90. Recently, a technique called Easi-CRISPR (Efficient additions with ssDNA inserts-
CRISPR) has been described in mice and demonstrates higher efficiency in producing floxed 
alleles and reporter insertion. The technique uses long ssDNA donors with short homology 
arms and it is proposed that the SSA repair pathway might mediate integration into the 













Figure 1.7 Repair mechanisms following a DSB in the DNA. The NHEJ repair mechanism 
does not involve resection, instead the ends are protected and ligated back together- 
often without error. HR, SSA and Alt-NHEJ/MMEJ all involve resection of the DNA, and 
repair either through local homology (resulting in deletion of intervening DNA) or from a 






1.13 Project Rationale 
Mutations in PRRT2 cause a series of paroxysmal disorders, including BFIE and PKD. At the time 
of its link to disease, very little was known about the function of PRRT2 or its pathogenic role in 
disease. Recent publications have shown a synaptic function for PRRT2, likely as part of the 
calcium sensing machinery facilitating exocytosis at the synapse. In Chapter 2 we aim to 
characterise the Prrt2 transgenic knockout mouse as a model for these diseases. 
At the outset of the project, we envisaged that investigations into the role of PRRT2 in disease 
using the Prrt2 KO mouse model would constitute the entire PhD. However, the mild 
phenotype and numerous recent publications necessitated additional studies to be added to 
this thesis.  
The studies presented in Chapter 3 and 4 investigate facets of CRISPR/Cas9 genome editing. 
The technology has revolutionised the production of genetically modified mice, making the 
process faster and more efficient. In Chapter 3 we aim to broaden the targetable regions of the 
mouse genome by testing a series of endonuclease variants with altered PAM recognition.  
Given the relative ease of producing genetically modified mice using CRISPR/Cas9, more 
possibilities have opened up with the type of modifications that can be introduced. One such 
modification is the addition of an epitope tag to a protein of interest, allowing visualisation in 
vivo with a commercially available antibody. The study presented in Chapter 4 aims to 
compare HA and FLAG antibodies on an endogenously tagged protein to demonstrate which 




Chapter 2:         
Paroxysmal and cognitive 






Mutations in PRRT2 cause a spectrum of episodic disorders. An understanding of the 
mechanism by which this occurs will help to direct treatment options for patients, improving 
quality of life. Investigations into the function of PRRT2 in vitro have provided insight into its 
involvement in synaptic vesicle exocytosis, as well as showing that loss of function Prrt2 
mutations result in defects in synaptic transmission 26. To better understand how these defects 
in cells translate to the paroxysms observed in patients, analysis of a disease model with 
complex neuronal networks is particularly interesting. As such, two recent studies have 
investigated mice lacking PRRT2 protein. Both groups observed spontaneous and induced 
motor paroxysms, in addition to abnormal electrophysiology in the brains of these mice27, 33.  
In this manuscript, we performed further phenotypic characterisation of the transgenic Prrt2 
KO mouse. After showing a loss of PRRT2 protein in mice homozygous for the knockout allele 
(KO) and reduction in heterozygous animals (HET), we confirmed the synaptic localisation of 
PRRT2. We also performed transmission electron microscopy to look at synaptic density and 
characteristics in KO cortex compared to wild type and showed that protein levels of PRRT2 
interactors Syt1/2 are unaffected by PRRT2 knockout. Most notably, we describe spontaneous 
phenotypes in a subset of animals, including spontaneous seizures in KO and unexpected death 
in both HET and KO. To further investigate the motor phenotype of this mouse model, we 
undertook a series of behavioural tests including locomotor, rotarod and digigait. Whilst no 
deficits were observed in locomotion or latency to fall in the rotarod, Prrt2 KO mice showed 
differences across a number of fundamental aspects of gait. We also assessed the cognitive 




including the MWM platform reversal. Mice showed learning deficits in MWM training days, 
though memory was unaffected. Overall, this manuscript extends the phenotype of Prrt2 KO 
mice, describing new epilepsy, motor and cognitive phenotypes that reflect the disease 
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Mutations in proline-rich transmembrane protein 2 (PRRT2) cause a range of episodic 
disorders that include paroxysmal kinesigenic dyskinesia (PKD) and benign familial infantile 
epilepsy (BFIE).  Mutations are generally loss of function and include the c649dupC frameshift 
mutation that is present in around 80% of affected individuals. To investigate how Prrt2 loss of 
function mutations cause disease, we performed a phenotypic investigation of a transgenic 
Prrt2 knockout (Prrt2 KO) mouse. We observed spontaneous paroxysmal episodes with 
behavioural features of both seizure and movement disorders, as well as unexpected deaths in 
KO and HET animals. KO mice showed spatial learning deficits in the Morris water maze, as well 
as gait abnormalities in the quantitative Digigait analysis; both of which may be representative 
of the more severe phenotypes experienced by homozygous patients. These findings extend 
the described phenotypes of Prrt2 mutant mice, further confirming their utility for in vivo 





Heterozygous mutations in proline-rich transmembrane protein 2 (PRRT2) cause a range of 
episodic neurological disorders, most commonly benign familial infantile epilepsy (BFIE), 
paroxysmal kinesigenic dyskinesia (PKD) and infantile convulsions with choreoathetosis (ICCA) 
1-3.  BFIE is an infantile epileptic seizure disorder with an onset at 3-12 months and offset 
around 2 years of age, without developmental impediment. In contrast, PKD is a movement 
disorder characterised by short bursts of hyperkinetic movement. Onset occurs in adolescence 
and symptoms persist into adulthood. ICCA is defined by the occurrence of BFIE and PKD in the 
same patient. PRRT2 mutations have also been implicated in other paroxysmal conditions, 
including other movement disorders, hemiplegic migraine and febrile seizures 4-8. A number of 
patients with homozygous mutations in PRRT2 have also been reported and show increased 
severity of episodic disorders, along with intellectual disability 9-11. The most common disease-
causing mutations result in frameshift and premature termination (for example c649dupC 
which occurs in almost 80% of patients) indicating a likely loss of protein function 12.  
Following its association with disease, investigations into the function of PRRT2 have revealed 
a primarily CNS-restricted protein, with a role in synaptic function 1, 13. PRRT2 spans 340 amino 
acids and contains two hydrophobic domains at the C-terminus, resulting in a membrane-
bound protein of which the majority is intracellular 1, 14. It is expressed throughout the brain, 
with strongest expression in the cerebellum, hippocampus and cortex 1, 15, 16. PRRT2 interacts 
with SNARE complex proteins SNAP-25, STX1A and VAMP2, as well as Ca2+ sensors Syt1/2, all of 
which are important regulators of synchronous neurotransmitter release at the pre-synaptic 




binds and negatively regulates voltage-gated Na+ channels Nav1.2 and Nav1.6, resulting in 
increased Na+ currents in homozygous cells 19. In vitro knockdown in primary neurons results in 
synaptic defects; namely decreased synaptic contacts, reduced synchronous neurotransmitter 
release and an insensitivity to extracellular Ca2+ 18. A role for PRRT2 in inhibition of vesicle 
fusion at the synapse has also been described 20.  Silencing of PRRT2 in vivo causes delayed 
neuronal migration during development and decreased dendritic spine density 21.  
Recently, two groups have described mouse models lacking PRRT2 protein. Both observed 
paroxysmal phenotypes including spontaneous PKD-like behaviours, motor abnormalities, 
audiogenic movement episodes and increased seizure susceptibility/severity following 
stimulation with pentylentetrazol (PTZ) 15, 16. In this study, we extend the phenotypic 
investigation of the Prrt2 knockout (Prrt2 KO) mouse as a model for Prrt2-related disorders. 
We find that similar to patients with PRRT2 mutations, Prrt2 KO mice display a spontaneous 
movement disorder and seizure phenotype. We also observe premature death in both 
heterozygous (HET) and KO animals, along with learning deficiencies and gait abnormalities in 
the latter. These findings further validate this mouse model as a valuable experimental tool for 






Materials and methods 
Animal housing and genotyping 
All animal work was conducted following approval by The University of Adelaide Animal Ethics 
Committee (approval numbers S-2013-201, S-2014-148, S-2016-136) in accordance with the 
Australian code for the care and use of animals for scientific purposes. Nine heterozygous Prrt2 
founders were provided by the Australian Phenomics Network at Monash University 
(Melbourne, Australia) and maintained on a C57BL/6N genetic background. Animals were 
housed in an animal facility at the University of Adelaide on a 12-hour light/dark cycle and 
provided water and food ad libitum with meat free rat and mouse diet (Specialty Feeds, 
Western Australia). Genomic DNA for routine genotyping was obtained from tail tips or ear 
notches at weaning (3 weeks) and amplified using a multiplex PCR. The common forward 
primer 5’-CTGGTGCGCCTTCGAGTTGG-3’ amplifies with Primer 2 5’-CTGGGACCTTCTGTCTGG-3’ 
for a WT allele or with Primer 3 5’-CAACGGGTTCTTCTGTTAGTCC-3’ for a transgenic allele. For 
amplification of inside the transgene to 3’ outside the transgene, the forward primer 5’-
GTCTGAGCTCGCCATCAGTT-3’ and reverse primer 5’-GACAGCATTGAGACGTGAGC-3’ were used. 
RT-PCR 
RNA was extracted from brain tissue using Trizol reagent (Thermofisher Scientific).  RNA was 
converted to cDNA using high capacity RNA-cDNA kit (Thermofisher Scientific). For 
amplification of lacZ forward primer 5’- TACGATGCGCCCATCTACAC-3’ and reverse primer 5’-




CTGTCAACATTGTGGCCTTC-3’ and reverse primer 5’- GCAAAAGTGCAGGGAGAAAG-3’ were 
used.  
Protein extraction and western blotting 
Brains were homogenized in extraction buffer (10mM Tris-HCl [pH 7.2], 150mM NaCl, 5mM 
EDTA, 1% Triton-X-100, 1% SDS, 1% Deoxycholate) with EDTA-free Protease Inhibitor Cocktail 
(Roche) and incubated at 4C for 30 minutes. For chemical fractionation, Syn-PER reagent 
(Thermo Fisher Scientific) was used as per manufacturer’s instructions. Lysates were separated 
on Invitrogen Bolt precast 4-12% polyacrylamide gels and transferred to PVDF membrane 
before blotting. Membranes were blocked for 1 hour in blocking solution (5% BSA, 5% skim 
milk) at room temperature and then incubated in primary antibody/blocking solution overnight 
at 4C. Primary antibodies and their corresponding dilutions were: rabbit anti-PRRT2 (1/2000, 
Sigma #HPA014447), rabbit anti-Syt1 (1/1000, Synaptic Systems #105103), rabbit anti-Syt2 
(1/1000, Synaptic Systems #105123), rabbit anti--actin (1/1000, Cell Signalling #4967), mouse 
anti-PSD95 (1/2000, Thermo Fisher Scientific #MA1046) and rabbit anti-synaptophysin 
(1/10000, Abcam #ab32127). Membranes were washed 3x in TBST and incubated for 2hrs at 
RT in secondary antibody conjugated with HRP/blocking solution at 1/400 dilution. Blots were 
washed and then imaged by chemiluminescence. For densitometric quantification, three 
biological replicates were performed and quantified using Biorad Chemidoc with Image Lab 
software. Each band was normalized to its -actin control, then to the relevant WT band. One-
way ANOVA was performed to analyse statistical differences using GraphPad Prism 7 software 






3-4week old mice were trans-cardially perfused with ice-cold PBS followed by ice-cold 4% PFA 
(n=3 WT, n=3 KO). The brains were then dissected and 1mm pieces of cortex fixed in TEM 
fixative (4% Sucrose, 4% Paraformaldehyde, 1.25% Gluteraldehyde in PBS). Tissue was 
postfixed for 1 h with osmium tetraoxide (2% aqueous solution) before dehydration in 
increasing ethanol concentrations, washing in propylene oxide and then embedding in 
Procure-812. Tissue was cut into ultra-thin sections (80nm), stained with uranyl acetate and 
lead citrate and imaged on the FEI Tecnai G2 Spirit transmission electron microscope. Images 
were analysed using Image J software and two-tailed unpaired t-test used for statistical 
comparison using GraphPad Prism 7 software.   
Nocturnal monitoring 
Nocturnal monitoring was performed by recording with an infrared camera mounted above a 
Perspex-covered cage in which mice had free access to food and hydration gel. Each mouse 
was recorded for 12 hours. Video footage was reviewed for overt behavioural phenotypes.  
PTZ assay 
Seizure susceptibility was measured by subcutaneous injection of pentylenetetrazole (PTZ) 
(120 mg/kg). Prrt2 WT, HET and KO mice (n=5 per genotype) were observed individually in 
clear cylinders for drug-induced seizure phenotypes culminating in tonic-clonic seizure, at 






Behavioural testing was carried out at the Florey Institute Behaviour Core facility (Melbourne, 
Australia). 8-week old mice (n=10 WT and n=14 KO) were taken through a series of behavioural 
tests (locomotor, rotarod, Y-maze, digigait, Morris water maze and reversal) over a number of 
weeks.  
Locomotor 
27.5cm square clear Perspex locomotor arenas (Tru-Scan) were used for testing with 16 IR 
beams on the lower sensor ring to detect floor plane movement and 16 on an elevated ring to 
detect rearing. Locomotive activity and rearing behaviour was recorded by the IR beam sensors 
over 30 minutes. 
Digigait 
Animals were placed inside the testing chamber positioned on a clear Perspex treadmill belt. 
The treadmill was started at a low speed (10cm/sec) until the animal was comfortable walking 
on the treadmill. The speed was slowly increased to 15, 20 or 25cm/s and then approximately 
15 steps captured before returning the mouse to its home cage.  
Rotarod 
Mice were pre-trained on the rotarod (Ugo Basil) for 3, 5-minute trials. The first 2 trials were 
run at a constant speed of 4 rpm, and the 3rd had an accelerating speed ranging from 4 - 40 




trial consists of the accelerating setting (4 – 40 rpm) across the 5-minute trial. An inter-trial 
interval of ~30 mins was included for each animal. 
Spontaneous alternation using Y-maze 
Testing took place in a Y-shaped maze with three Perspex arms at a 120 angle from each 
other. After introduction to the centre of the maze, the animal was allowed to freely explore 
the three arms. The number of arm entries and the number of triads were recorded in order to 
calculate the percentage of alternation. An entry was scored when all four limbs were within 
the arm.  
Morris Water Maze and reversal 
The 1.2m diameter water maze pool was filled to a depth of 40cm with 22 degree C water. This 
leaves the 15cm diameter submerged platform 1cm below the water level. Approximately 
500ml of non-toxic white paint was added to the water to make it opaque and hide the 
platform from the animal. The mouse was then placed in the pool at one of the cardinal points 
(N, E, S, W) in a randomized fashion and allowed 1 minute to find the platform. If the mouse 
found the platform within this time it was allowed 10 seconds on the platform before it was 
removed, gently towelled down and placed under a warming lamp. If the mouse did not find 
the platform within the 2 minutes, it was led to the platform by trailing a hand in the water in 
front of the mouse. It was then allowed 10 seconds on the platform before it was removed, 
towelled down and placed under a warming lamp. The routine was repeated 4 times per day 
for 6 days with an interval time between swims of 20-30 minutes, until the mouse had clearly 





Rotarod, morris water maze and reversal data were assessed using linear mixed effects 
models. Where data violated distributional assumptions, it was transformed to geometric 
means for analysis, however arithmetic means are reported. For tests with maximal time 
constraints (censored data), linear mixed effects tobit models were used for statistical analysis. 
Locomotor data was analysed using the Wilcoxin test. Linear mixed effects models and 
Wilcoxin tests were completed using SAS v9.4 (SAS Institute, Cary, NC, USA). Digigait 
parameters were analysed using two-way ANOVA and post-hoc Sidak tests. Unpaired two-
tailed students t-tests were used for analysis of the continuous Y-maze. PTZ survival plots were 







Prrt2 KO mice 
Prrt2 KO mice were generated using pre-targeted ES cells purchased from KOMP (part of the 
International Knockout Mouse Consortium - IKMC) by ES2M/Australian Phenomics Network 
Facility at Monash University (Melbourne, Australia). They carry a ‘knockout first’ allele, 
encoding an engrailed (En2) splice acceptor and IRES-LacZ transgene between exon 1 and 2 of 
the Prrt2 locus, which is preferentially spliced resulting in PRRT2 knockout (Supplementary 
Figure 1a). We first established that homozygous (KO) and heterozygous (HET) Prrt2 mice 
expressed the IRES-LacZ transgene and that KO animals lack the Prrt2 ORF using RT-PCR 
(Supplementary Figure 1b). Western blot analysis on adult whole brain extract confirmed 
reduced PRRT2 protein in HET and an absence in Prrt2 KO animals (Supplementary Figure 1c). 
To confirm the location of the transgene, genomic DNA from heterozygous founders was PCR 
amplified using a primer outside of the transgene homology arms to within (Supplementary 
Figure 1d).  
Chemical fractionation on adult brain samples confirmed that PRRT2 is present in the 
synaptosome but not the cytosolic fraction (Supplementary Figure 2a). Given that PRRT2 has 
been shown to interact with SYT1/2, and that knockdown of PRRT2 in primary neurons results 
in lower SYT1 and 2 levels18, we assessed SYT1/2 protein levels in brain lysates by western blot. 
No significant change in SYT1 or SYT2 was detected in the brains of Prrt2 HET or KO mice.  The 
levels of other synapse proteins, synaptophysin and PSD95 were similarly unaffected by 
reduction or absence of PRRT2 (Supplementary Figure 2b). Transmission electron microscopy 




synapse density (p=0.1824; Supplementary Figure 2c) or active zone length (p=0.0781; 
Supplementary Figure 2d). 
Spontaneous paroxysms and sudden unexplained death in Prrt2 mice 
PRRT2 disorders are characterised by spontaneous paroxysms, which manifest as epileptic 
seizures and/or a movement disorder. Consistent with these clinical features, we observed 
spontaneous paroxyms in Prrt2 KO mice. These events were observed during routine handling 
in a small proportion of Prrt2 KO animals, without an obvious trigger (2.53%, Figure 1). 
Episodes lasted for varying lengths of time and affected mice across a range of ages (5 weeks 
to 8 months). Episodes began with dyskinesia and were sometimes followed by secondary 
generalized seizures (which was accompanied by loss of awareness; Supplementary Video 1+ 
2). To determine whether spontaneous paroxysms were occurring during routine housing, we 
performed infrared video monitoring of a small cohort during the dark cycle (the active period 
for mice). Overt behavioural phenotypes were not detected in either HET or KO mice (data not 
shown). We also assessed seizure susceptibility by performing a PTZ assay on a cohort of WT, 
HET and KO adult mice (n=5 per genotype) but observed no significant difference in latency to 
tonic-clonic seizure (Supplementary Figure 3).  
Interestingly, Prrt2 KO and HET mice also displayed a marked survival defect with 7.69% of KO 
and 1% of HET mice found dead in their cages, without any clear cause of death (Figure 1). 
Both the spontaneous paroxysms and unexplained deaths were not observed in WT animals 





Gait alteration in Prrt2 KO mice  
To assess motor activity and coordination in Prrt2 KO mice, we performed locomotor, digigait 
and rotarod behavioural testing. Given that phenotypic severity is greater in PRRT2 
homozygous patients, we compared Prrt2 KO (n=14) and WT (n=10) mice. Locomotor analysis 
showed no overall difference in movement or activity between Prrt2 KO and WT 
(Supplementary Figure 4a). No significant difference was observed between groups of animals 
on the Rotarod test, indicating that Prrt2 mice do not suffer from coordination issues 
(Supplementary Figure 4b).  
Quantitative comparison of gait was performed using digigait analysis across three speeds (15, 
20 and 25cm/s). Interestingly, significant differences were detected between WT and KO mice 
across most aspects of gait including stride, swing, stance and brake. Stride length was 
significantly lower, whilst number of steps and step frequency were significantly higher in KO 
animals (Figure 2, Table 1). To further define these differences, post hoc Sidak multiple 
comparison tests were performed. This analysis revealed significant differences between WT 
and KO mice at 15cm/s and to a large extent at 20cm/s, but not at 25cm/s (Supplementary 
Table 1). To rule out the possibility that animal size was the cause of the differences, we 
compared animal length between WT and KO animals and saw no significant difference 
(p=0.3671, Supplementary Figure 4c). Altogether, digigait analysis on Prrt2 KO mice show a 






Prrt2 KO mice display learning deficiencies 
Given that intellectual disability is observed in homozygous patients, we investigated the 
cognitive abilities of KO mice. When tested on the continuous Y-maze, there was no significant 
difference between Prrt2 KO and WT animals in percentage alternation between arms 
(p=0.1314; Supplementary Figure 5a).  
In the Morris Water Maze, Prrt2 KO mice displayed significantly longer latency to reach the 
platform than WT (p=0.014, Figure 3a). Post hoc analysis confirmed an overall genotype 
difference that was independent of trial day. When we measured distance travelled and 
velocity in Morris Water Maze, no differences were observed between KO and WT, indicating 
that differences observed were due to cognitive deficits rather than reduced or slower 
swimming ability (Supplementary Figure 5b-e). When spatial memory was tested during the 
probe trial, there was no significant difference in target quadrant time between genotypes 
(p=0.083, Figure 3c). Repeating the Morris Water maze with reversal of the platform resulted 
in no differences between genotypes in latency to reach the platform across 5 days nor in 
target quadrant time in a reversal probe test (p=0.906 or 0.693 respectively, Figure 3d,e). 







Heterozygous loss of function mutations in PRRT2 cause a broad spectrum of episodic diseases, 
most frequently BFIE and PKD. Analysis of gene function using knockdown techniques has 
revealed a synaptic function for the protein, as well as a possible role in neuronal 
development18, 21.  
In order to investigate the impact of Prrt2 mutations in vivo we undertook phenotypic analysis 
of a Prrt2 KO mouse. Consistent with a recent report on the same transgenic model, we 
observed no detectable protein or transcript in the brains of KO animals, with reduced levels in 
heterozygous mutants 15. PRRT2 localised to the synapse as previously reported 13, 16, 18, 21, 
though its reduction or knockout did not change levels of SYT 1/2 in vivo as observed in PRRT2 
knockdown neurons 18. When we assessed cortical synaptic density by TEM, we saw no 
significant differences between WT and Prrt2 KO brains. The same observation was recently 
described in the cerebellum of a Prrt2STOP mouse that models the recurrent c649dupC 
mutation in patients 16. Interestingly, Michetti et al reported decreased synaptic contacts in the 
dentate gyrus (DG) but not in two regions of the cerebellum. Similarly, they observed that 
mRNA expression levels of most synaptic markers were not altered in the cortex of Prrt2 HET 
or KO animals 15. This suggests that although Prrt2 is expressed broadly throughout the brain, it 
may be playing a different role in the DG compared to other brain regions.  
We describe a series of behavioural phenotypes in Prrt2 KO mice that model clinical 
phenotypes observed in humans. Most notably, spontaneous paroxysms were detected in 
Prrt2 KO mice, albeit at low penetrance. A similar phenotype was described by Tan et al, with 




previous analysis of the Prrt2 KO model, when we probed the seizure susceptibility by PTZ 
injection, we observed no difference in latency to tonic-clonic seizure for both Prrt2 HET and 
KO mice, though the previous study observed more severe seizures once induced 15. In 
contrast, increased seizure susceptibility was observed in Prrt2STOP mice using both a PTZ and 
febrile seizure assay 16. The models are maintained on different C57BL/6 substrains, which 
have genotypic and phenotypic differences that may impact on performance in behavioural 
tests22. We also identified unexplained death in a subset of Prrt2 mutant (HET and KO) animals 
(Figure 1). Though not a common feature of PRRT2 mutations in humans, a heterozygous 
patient with probable sudden unexpected death in epilepsy (SUDEP) has been reported 23. 
Other murine models of genetic epilepsies have also been identified with a premature death 
phenotype, although it is not clear if the primary cause of death is related 24, 25.  
Whilst most PRRT2-related disorders are paroxysmal in nature, homozygous patients 
experience increased severity of disease, along with additional intellectual and learning 
disabilities 10, 11. Consistent with these phenotypes, we observed learning defects in Prrt2 KO 
mice when testing their spatial learning in the Morris Water Maze (Figure 3b). However, 
working memory and memory plasticity were unaffected as evidenced by the probe test and 
platform reversal 26. Rotarod and locomotor tests did not reveal a motor or coordination 
phenotype for the Prrt2 KO mice in our study, despite the coordination differences described 
in Prrt2STOP mice 16.  Prrt2 KO mice also displayed gait abnormalities when assessed on the 
Digigait software. These abnormalities span many fundamental gait parameters and 
manifested when travelling at the slowest treadmill speed (15cm/s) during digigait analysis 
(Table 1, Supp Table 1). Interestingly, these differences were not as pronounced at the faster 




be speed-dependent, with faster speeds (akin to running) masking phenotypes observed at 
slower (walking) speeds (unpublished observations, T. Featherby). Previously reported 
footprint analysis of Prrt2 mice showed no differences between genotypes, however many 
aspects of gait that differed here were not tested and mice were not controlled for speed 15, 16. 
Movement disorders experienced by patients with PRRT2 mutations are typically episodic in 
nature, making the finding of overall gait differences somewhat unexpected. We cannot rule 
out the possibility that subtle movement episodes were experienced by a subset of KO animals 
during testing, resulting in the overall gait deficit attributed to the group, however given the 
lack of significant differences at the fastest speed, this seems unlikely. It remains to be seen 
how Prrt2 HET animals perform in these same behavioural experiments.  However, we expect 
that learning and gait phenotypes will not be present, given that Prrt2 heterozygosity in 
humans most commonly results in epileptic or motor paroxysms with an absence of other 
phenotypes. 
Together, our phenotypic investigation of the Prrt2 KO mouse revealed a paroxysmal 
phenotype in KO, along with premature death affecting HET and KO animals. Wide-ranging gait 
abnormalities and learning deficits were also observed in KO mice. These data support Prrt2 
KO mice as a useful model for investigating Prrt2 function and elucidation of disease 
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Figure 1: Proportions of Prrt2 HET and KO animals that experienced spontaneous death 
and seizures. Animals that were found dead are represented by orange shading, those 
that experienced spontaneous paroxysms are in green and unaffected mice are indicated 








Figure 2: Gait deficiencies in Prrt2 KO mice. (a,b) Stride time across three speeds (15, 20 & 
25 cm/s) was significantly lower in KO compared to WT in both fore (p=0.0054) and hind 
limbs (p=0.0019). (c,d) Prrt2 KO mice showed shorter stride length than WT in both fore 
(p=0.0109) and hind limbs (p=0.0052) across the three speeds. Differences between 
genotypes were analysed with two-way ANOVA. Error bars indicate mean  SD. n=10 WT 





Figure 3: Learning disabilities in Prrt2 KO mice (a) Prrt2 KO mice show significantly longer 
latency to platform in the Morris Water Maze (MWM) training days (p=0.014). This 
difference was independent of day. (b) Percentage of time spent in each quadrant during 
the probe trial with the platform removed. The platform had previously been in the NE 
quadrant during training days. Differences between WT and KO were not significant 
(p=0.083). (c) The platform was moved to the SW quadrant for the MWM reversal. 
Latency to find platform across the 5 reversals days was not significant between WT and 
KO (p=0.906). (d) Percentage time spent in each quadrant during the reversal probe trial. 
Differences between WT and KO were not significant (p=0.693). MWM and reversal 
training day analyses were performed using a linear mixed effects tobit model. Probe data 
was analysed using a linear mixed effects model. Data expressed as mean  SD. n=10 WT 






1. Chen WJ, Lin Y, Xiong ZQ et al. Exome sequencing identifies truncating mutations in 
PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet. 2011;43:1252-1255. 
DOI: 10.1038/ng.1008 
2. Wang JL, Cao L, Li XH et al. Identification of PRRT2 as the causative gene of paroxysmal 
kinesigenic dyskinesias. Brain. 2011;134:3493-3501. DOI: 10.1093/brain/awr289 
3. Heron SE, Grinton BE, Kivity S et al. PRRT2 mutations cause benign familial infantile 
epilepsy and infantile convulsions with choreoathetosis syndrome. Am J Hum Genet. 
2012;90:152-160. DOI: 10.1016/j.ajhg.2011.12.003 
4. Liu Q, Qi Z, Wan XH et al. Mutations in PRRT2 result in paroxysmal dyskinesias with 
marked variability in clinical expression. J Med Genet. 2012;49:79-82. DOI: 
10.1136/jmedgenet-2011-100653 
5. Cloarec R, Bruneau N, Rudolf G et al. PRRT2 links infantile convulsions and paroxysmal 
dyskinesia with migraine. Neurology. 2012;79:2097-2103. DOI: 
10.1212/WNL.0b013e3182752c46 
6. Gardiner AR, Bhatia KP, Stamelou M et al. PRRT2 gene mutations: from paroxysmal 
dyskinesia to episodic ataxia and hemiplegic migraine. Neurology. 2012;79:2115-2121. 
DOI: 10.1212/WNL.0b013e3182752c5a 
7. Marini C, Conti V, Mei D et al. PRRT2 mutations in familial infantile seizures, paroxysmal 
dyskinesia, and hemiplegic migraine. Neurology. 2012;79:2109-2114. DOI: 
10.1212/WNL.0b013e3182752ca2 
8. Scheffer IE, Grinton BE, Heron SE et al. PRRT2 phenotypic spectrum includes sporadic 
and fever-related infantile seizures. Neurology. 2012;79:2104-2108. DOI: 
10.1212/WNL.0b013e3182752c6c 
9. Ebrahimi-Fakhari D, Saffari A, Westenberger A et al. The evolving spectrum of PRRT2-
associated paroxysmal diseases. Brain. 2015;138:3476-3495. DOI: 
10.1093/brain/awv317 
10. Labate A, Tarantino P, Viri M et al. Homozygous c.649dupC mutation in PRRT2 worsens 
the BFIS/PKD phenotype with mental retardation, episodic ataxia, and absences. 




11. Delcourt M, Riant F, Mancini J et al. Severe phenotypic spectrum of biallelic mutations 
in PRRT2 gene. J Neurol Neurosurg Psychiatry. 2015;86:782-785. DOI: 10.1136/jnnp-
2014-309025 
12. Heron SE, Dibbens LM. Role of PRRT2 in common paroxysmal neurological disorders: a 
gene with remarkable pleiotropy. J Med Genet. 2013;50:133-139. DOI: 
10.1136/jmedgenet-2012-101406 
13. Lee HY, Huang Y, Bruneau N et al. Mutations in the gene PRRT2 cause paroxysmal 
kinesigenic dyskinesia with infantile convulsions. Cell Rep. 2012;1:2-12. DOI: 
10.1016/j.celrep.2011.11.001 
14. Rossi P, Sterlini B, Castroflorio E et al. A Novel Topology of Proline-rich Transmembrane 
Protein 2 (PRRT2): hints for an intracellular function at the synapse. J Biol Chem. 
2016;291:6111-6123. DOI: 10.1074/jbc.M115.683888 
15. Michetti C, Castroflorio E, Marchionni I et al. The PRRT2 knockout mouse recapitulates 
the neurological diseases associated with PRRT2 mutations. Neurobiol Dis. 2017;99:66-
83. DOI: 10.1016/j.nbd.2016.12.018 
16. Tan GH, Liu YY, Wang L et al. PRRT2 deficiency induces paroxysmal kinesigenic 
dyskinesia by regulating synaptic transmission in cerebellum. Cell Res. 2017. DOI: 
10.1038/cr.2017.128 
17. Valtorta F, Benfenati F, Zara F et al. PRRT2: from Paroxysmal Disorders to Regulation of 
Synaptic Function. Trends Neurosci. 2016;39:668-679. DOI: 10.1016/j.tins.2016.08.005 
18. Valente P, Castroflorio E, Rossi P et al. PRRT2 Is a Key Component of the Ca(2+)-
Dependent Neurotransmitter Release Machinery. Cell Rep. 2016;15:117-131. DOI: 
10.1016/j.celrep.2016.03.005 
19. Fruscione F, Valente P, Sterlini B et al. PRRT2 controls neuronal excitability by 
negatively modulating Na+ channel 1.2/1.6 activity. Brain. 2018;141:1000-1016. DOI: 
10.1093/brain/awy051 
20. Coleman J, Jouannot O, Ramakrishnan SK et al. PRRT2 Regulates Synaptic Fusion by 
Directly Modulating SNARE Complex Assembly. Cell Rep. 2018;22:820-831. DOI: 
10.1016/j.celrep.2017.12.056 
21. Liu YT, Nian FS, Chou WJ et al. PRRT2 mutations lead to neuronal dysfunction and 





22. Simon MM, Greenaway S, White JK et al. A comparative phenotypic and genomic 
analysis of C57BL/6J and C57BL/6N mouse strains. Genome Biol. 2013;14:R82. DOI: 
10.1186/gb-2013-14-7-r82 
23. Labate A, Tarantino P, Palamara G et al. Mutations in PRRT2 result in familial infantile 
seizures with heterogeneous phenotypes including febrile convulsions and probable 
SUDEP. Epilepsy Res. 2013;104:280-284. DOI: 10.1016/j.eplepsyres.2012.10.014 
24. Massey CA, Sowers LP, Dlouhy BJ et al. Mechanisms of sudden unexpected death in 
epilepsy: the pathway to prevention. Nat Rev Neurol. 2014;10:271-282. DOI: 
10.1038/nrneurol.2014.64 
25. Palmer EE, Jarrett KE, Sachdev RK et al. Neuronal deficiency of ARV1 causes an 
autosomal recessive epileptic encephalopathy. Hum Mol Genet. 2016;25:3042-3054. 
DOI: 10.1093/hmg/ddw157 
26. Tsetsenis T, Younts TJ, Chiu CQ et al. Rab3B protein is required for long-term depression 
of hippocampal inhibitory synapses and for normal reversal learning. Proc Natl Acad Sci 













WT vs KO Sidak adjusted p-
value 
Treadmill Speed 


























































































































































Supplementary Table 1: Genotype comparisons from two-way ANOVA analyses of 







Supplementary Figure 1: Characterisation of Prrt2 KO mice. a) Schematic of the wild type 
Prrt2 and transgene alleles with primers for PCR marked above. The Engrailed 2 Splice 
Acceptor (En2) is preferentially spliced, resulting in transcription of the IRES-LacZ gene in 
place of Exon 2-4. Promoter driven neomycin resistance gene (neo) and Exon 2 are 
flanked by LoxP sites giving conditional potential. b) RT-PCR from Exon 2-4 of Prrt2 
confirms amplification in WT and HET, whilst LacZ amplifies only in HET and KO animals. c) 
Western blot analysis on adult whole brain lysates, confirming complete lack of PRRT2 in 
KO and reduction in HET. d) PCR analysis from inside to outside the transgene to confirm 












Supplementary Figure 2: Molecular and ultrastructural analysis of Prrt2 mutant brains. a) 
Subcellular fractionation of adult mouse cortex, confirming localisation of PRRT2 to the 
synaptosome fraction, similar to synaptic markers PSD95 and Synaptophysin. W= whole 
cell extract, C=cytosolic fraction, S=synaptosome. n=3 biological replicates per genotype. 
b) Western blot analysis on adult whole brain comparing levels of Synaptotagmins 1/2 
(Syt1/2), PRRT2 and synaptic markers PSD95 and Synaptophysin. c) Densitometric 
quantification of b) normalized to WT. All data are expressed as means  SD and 
analysed using one-way ANOVA (ns=not significant). n=3 biological replicates for each 
genotype. d) Sample images from transmission electron microscopy on cortical sections 
from Prrt2 WT and KO mice. e) Quantification of synapse number and length from n=3 









Supplementary Figure 3: Prrt2 mice do not show increased seizure susceptibility 
following subcutaneous pentylenetetrazol (PTZ) injection. Data expressed as a survival 
curve of latency to tonic-clonic seizure and analysed using the Mantel-Cox test (p=0.9880) 






Supplementary Figure 4: Locomotor activity and coordination in Prrt2 KO mice are not 
significantly different to wildtype. a) WT and KO performance across locomotor 
parameters. Data expressed as mean  SD and significance analysed using Wilcoxon test. 
VP- vertical plane, FP- Floor plane b) Latency to fall from accelerating Rotarod across 
three trials on consecutive days. Data expressed as mean  SD and analysed using linear 
mixed effects tobit model c) Animal length during digigait testing at three different 
speeds. Data expressed as mean  SD and analysed using two-way ANOVA. n=10 WT, 






Supplementary Figure 5: Continuous Y-Maze and Morris water maze (MWM) outcomes. 
a) Percentage alternation on the continuous Y-maze. Data expressed as mean  SD and 
analysed using unpaired t-test. b-e) MWM and reversal distance and speed across trial 






















Chapter 3:           
Expanding the RNA-guided 
endonuclease toolkit for 





As demonstrated in the previous chapter, mouse models are important tools for investigating 
biological questions and modelling human diseases. The advent of CRISPR/Cas technology has 
enabled the rapid and efficient production of mouse models through direct microinjection of 
genome editing agents in the zygote. Whilst the commonly used Cas9 protein from 
Streptococcus pyogenes (WT SpCas9) is incredibly efficient at introducing mutations in mice, 
the NGG PAM requirement restricts the targetable regions. An application particularly affected 
by this restriction is when introducing a point mutation via HDR, as mutation incorporation is 
directly affected by its distance from the double-stranded break. Variants of the CRISPR/Cas 
system have been described that recognise alternative PAM sequences, allowing more 
flexibility in targeting, though many of these have not been tested for mouse genome editing.   
In this submitted manuscript, we compare a series of CRISPR variants for their ability to 
introduce mutations in the mouse genome editing. We tested the following endonucleases, 
targeted to a site in the Ngn3 intron: SpCas9 VQR (NGAN PAM), SpCas9 VRER (NGCG PAM), 
AsCpf1 (TTTN PAM) and SaCas9 KKH (NNNRRT PAM), as well as the WT SpCas9 (NGG PAM). We 
showed efficient editing with WT SpCas9 (95%) and AsCpf1 (30%). We also validated SpCas9 
VQR and SpCas9 VRER for mouse genome editing though observed lower efficiencies (11% and 
6% respectively). The SaCas9 KKH variant generated mutations with high efficiency (56%), 
making it a useful alternative to WT SpCas9 with its flexible PAM site.  
We also observed an interesting difference in SaCas9 KKH mutant embryos when compared to 
WT SpCas9; where WT SpCas9 would cut both alleles frequently, SaCas9 KKH left an 




template for modification through HDR. All SaCas9 KKH mediated oligo insertions were 
accompanied by a WT allele, whilst only 50% of embryos with oligo insertions from WT SpCas9 
injections had a WT allele remaining. We propose that this property may be useful when 
targeting genes that cause embryonic lethality if mutated on both alleles.  
We confirmed efficient introduction of mutations in a second genomic locus using SaCas9 KKH 
(tyrosinase gene) and showed that mutations could be carried through the germline to 
establish a colony. This study extends the available ‘toolkit’ for mouse genome editing, 
validating CRISPR variants that will broaden PAM recognition options. It also explores a novel 
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The RNA-guided endonuclease CRISPR/Cas system from Streptococcus pyogenes (SpCas9) is 
widely used for generating genetically modified mice via zygote micro-injection. Although 
double-strand breaks (DSBs) are induced efficiently by SpCas9, it requires an NGG proto-spacer 
adjacent motif (PAM) at the target site, restricting sequence targetability. Recently, alternative 
RNA-guided endonucleases that utilise different PAM sequences have been characterised. 
Here we tested the following endonucleases for their ability to edit the mouse genome: SpCas9 
VQR (NGAN PAM), SpCas9 VRER (NGCG PAM), AsCpf1 (TTTN PAM) and SaCas9 KKH (NNNRRT 
PAM), alongside wild type (WT) SpCas9 (NGG PAM). SaCas9 KKH generated mutations in up to 
70% of embryos. Remarkably, in contrast to WT SpCas9, this variant left one allele unmodified 
in the vast majority of mutant embryos (6% versus 93%). Our findings not only broaden the 
PAM recognition options for mouse genome editing, but also identify SaCas9 KKH as an 






Genetically modified mice are widely used for investigating gene function, disease modelling 
and therapeutic development. The traditional method for generating targeted modifications in 
mice involves creation of mutant ES cells, injection of modified ES cells into blastocysts and 
breeding of chimeric founders 1. While this approach has proven useful, it is costly, time 
consuming and prone to failure due to the reliance on germline transmission. The 
development of CRISPR/Cas9 genome editing technology provides an alternative approach for 
the generation of mutant mice through direct modification of the zygotic genome 2-4.  This 
approach is efficient, fast and cheap, and has largely replaced traditional gene targeting.  
The most commonly used Cas9 endonuclease is derived from Streptococcus pyogenes 
(SpCas9). Target sequence specificity is provided by two features: a gRNA molecule that 
contains a 20bp sequence that is complementary to the target site and forms a complex with 
Cas9, and an NGG PAM (proto-spacer adjacent motif) located immediately in 3’ of the gRNA 
binding site that is essential for Cas9/DNA interaction. Cas9 cleavage generates a double-
stranded break (DSB) which is typically repaired by the non-homologous end joining (NHEJ) 
pathway, ultimately resulting in insertions or deletions (indels) due to misrepair. Generation of 
indels in exonic sequences can be used to create frameshift mutations and is therefore a useful 
approach to generate loss of function mutations. Alternatively, the homology directed repair 
(HDR) pathway can be exploited to introduce a specific sequence (eg. point mutation) at the 
cleavage site. This approach requires a ssDNA or dsDNA template DNA containing the mutation 




While CRIPSR/Cas9 technology has proven to be incredibly useful for producing targeted 
mutations, the availability of PAM sequences in the target region imposes a significant 
limitation on potential cleavage sites.  This restriction is particularly relevant for HDR-mediated 
mutagenesis using ssDNA templates where the efficiency of HDR insertion is maximised when 
the DSB is generated as close as possible to the intended sequence modification8. Different 
versions of the CRISPR/Cas9 system have recently been characterised, providing alternatives to 
overcome this issue; for example, the Class 2 CRISPR endonuclease Cpf1, which creates a 
staggered cut distal to its TTTN PAM sequence9-13. Additionally, engineered variants of Cas9 
from a number of species including SpCas9, Francisella novicida (FnCas9) and Staphylococcus 
aureus Cas9 (SaCas9) have been developed that use alternative PAM recognition sites 11; 13-15. 
Higher fidelity Cas9 variants have also been developed to reduce potential off-target DNA 
mutations 16-18.  
While Cpf1 and SaCas9 have been shown to produce heritable mutations in mice, several 
endonuclease variants remain untested 19-21. We selected and tested a number of 
programmable endonuclease proteins with the potential to expand the range of targetable 
sequences through their use of alternative PAM sequences. Here we validate SpCas9 VQR and 
VRER for mouse genome editing and demonstrate efficient targeted mutagenesis using the 
SaCas9 KKH variant.  We also show that this variant has a propensity to generate heterozygous 
mutations and provides a useful alternative to WT SpCas9 when targeting genes in which 





Materials and methods 
Generation of Cas9 variant/Cpf1 mRNAs 
Plasmids for each variant: MSP469 (SpCas9 VQR), MSP1101 (SpCas9 VRER), MSP1830 (SaCas9 
KKH), pY010 (pcDNA3.1- hAsCpf1) were obtained from Addgene (#65771,65773,70708,69982). 
pCMV/T7-hCas9 plasmid (Toolgen) was used for WT SpCas9. SaCas9 KKH was cloned into 
pBluescript to position a T7 promoter 5’ of the gene. Plasmids were linearized with XhoI or SalI 
and mRNA generated using mMESSAGE mMACHINE® T7 ULTRA Transcription Kit (Ambion). 
mRNAs were purified using RNEasy Mini kit (QIAGEN). 
sgRNA production 
sgRNAs were designed using CCTop- CRISPR target online predictor22. Guide oligonucleotides 
(Geneworks, Australia, Supplementary Table 1) were denatured at 95 °C for 5 minutes and 
annealed at 25 °C before being ligated into BbsI linearised px459 vector (Addgene, #62988) or 
BsmBI linearised BPK2660 vector (SaCas9 sgRNA, Addgene, #70709). A template for in vitro 
transcription was generated by PCR amplification of the pX459 vector using a forward primer 
containing a 5’ T7 promoter sequence and a reverse primer in the TracR sequence. In vitro 
transcription was performed using HiScribe T7 In Vitro Transcription Kit (NEB) and transcribed 
gRNA was purified using RNeasy Mini Kit (QIAGEN). For Cpf1 crRNA, an oligonucleotide (IDT) 
containing a T7 promoter sequence, gRNA and scaffold was used. In vitro transcription was 
performed using HiScribe T7 In Vitro Transcription Kit (NEB) and transcribed crRNA was 






C57BL/6 females were superovulated by injecting 5IU PMSG (Folligon; Intervet India) followed 
by 5IU hCG (Chorulon; Intervet India) 47.5 hours later. Superovulated females were mated to 
male C57BL/6 mice and fertilised oocytes were collected from oviducts in FHM (Merck 
Millipore). Oocytes were maintained in KSOMAA (Merck Millipore) at 37 °C in 5% CO2 and were 
screened for the presence of 2 pronuclei to indicate fertilization. Fertilised oocytes were 
microinjected (cytoplasmic) with buffered solution containing Cas9 variant mRNA and sgRNA 
(concentrations for each variant in Supplementary Table 2) in FHM before being transferred to 
the oviduct of pseudopregnant Swiss female mice. ssODN with phosphorothioate 
modifications on four nucleotides at the 5’ and 3’ end was included in mRNA/gRNA mix for 
HDR injections (Integrated DNA Technologies)23. 
All animal work was conducted in accordance with Australian guidelines for the care and use of 
laboratory animals following approval by The University of Adelaide Animal Ethics committee 
(approval number S-2016-049). 
Genomic DNA extraction 
gDNA was extracted from embryo or tail tip samples using High Pure PCR Template 
Preparation Kit (Roche) or KAPA Mouse Genotyping Kit (Kapa Biosystems). PCR products were 
amplified using primers specific to each target region (sequences in Supplementary Table 1). 
Heteroduplex Mobility Assay and RFLP analysis 
PCR products were resolved by polyacrylamide gel electrophoresis in non-denaturing gels with 




ammonium persulfate and TEMED with a low percentage stacker layer (4% acrylamide-
bisacrylamide solution). Prior to loading, PCR products (unmixed and mixed with WT) were re-
annealed to form heteroduplex products by heating to 95C for 5 minutes and slowly ramped 
down to room temperature. RFLP analysis was performed by mixing 5uL of PCR products with 
restriction enzyme and appropriate buffer (NEB) in a total volume of 20uL and incubating at 
the appropriate temperature for 90 minutes.  
Sanger sequencing and cloning 
PCR products were purified using QIAquick PCR purification kit (Qiagen) before being used as a 
template in a BigDye Terminator v3.1 reaction (ThermoFisher) with the forward PCR primer. 
Sequencing was performed by the Australian Genome Research Facility, Adelaide. For cloning, 
PCR products were ligated into pGEM-T easy vector (Promega) and resulting clones screened 
for the presence of a BsiHKAI restriction site. For each sample, a plasmid with and without the 






CRISPR variants create targeted mutations in vivo 
To assess emerging CRISPR and Cpf1 technologies for targeted mutagenesis in mice we 
microinjected mouse zygotes with mRNA encoding WT SpCas9, SpCas9 VQR, SpCas9 VRER, 
AsCpf1 or SaCas9 KKH and their cognate gRNAs (Table 1). To allow direct comparison of 
mutagenesis efficiencies, we targeted a region in the intron of Ngn3 in which all gRNA target 
sequences overlapped (Figure 1). Each endonuclease cleavage site also contained a restriction 
site permitting RFLP analysis for mutation detection.  
WT SpCas9 was initially selected for mutation analysis.  Zygotes were microinjected with WT 
SpCas9 mRNA and Ngn3 gRNA, transferred to pseudopregnant females and harvested at 10.5-
12.5 days post transfer (dpt) for analysis (Table 2). PCR products spanning the target site were 
generated from 19 of the 20 embryos harvested for analysis. The failure of one sample (sample 
12) to amplify across the Ngn3 target site may reflect generation of large deletions on both 
alleles resulting in loss of PCR primer binding sites, a frequent occurrence of WT SpCas9 DNA 
DSB repair (our unpublished data). Consistent with this conclusion, we were able to 
successfully amplify DNA from the Prrt2 locus (data not shown). We initially genotyped the 
samples using a polyacrylamide gel heteroduplex mobility assay (HMA). Analysis of PCR 
products revealed 12 of 19 samples harboured mutations (63.2%, Figure 2a, Supplementary 
Figure 1a). Interestingly, mixing samples in a 1:1 ratio with WT Ngn3 PCR product before HMA 
analysis increased the mutation rate to 17 of 19 samples (89.5%, Figure 2b, Supplementary 
Figure 1b). These data indicate that a single mutant allele was amplified in 5 samples 




homoduplexes for the PCR product HMA.  RFLP analysis with BsiHKAI confirmed these results, 
and revealed one additional mutant (sample 8) raising the total mutation rate to 18/19 (94.7%; 
Figure 2c, Supplementary Figure 1c). We sequenced several of these samples and observed 
indels ranging from 1bp insertions to 7bp deletions, confirming mutations resulting from 
SpCas9 DNA cleavage (data not shown).  Together these data validate our screening assays and 
confirm that SpCas9 generates targeted mutations with high efficiency. 
Next, we tested SpCas9 variants VQR and VRER, which recognise PAM sequences NGAN and 
NGCG, respectively. Mouse zygotes were microinjected with SpCas9 VQR or VRER mRNAs and 
corresponding gRNAs and transferred to pseudopregnant females. Embryos were harvested at 
11.5-12.5 dpt and subjected to the same mutation screening protocol. For VRER, only 1 mutant 
embryo was observed from 16 samples and findings were consistent across unmixed and WT 
mixed HMA, as well as RFLP analysis and sequencing (Supplementary Figure 2). VQR embryo 
analysis showed that 2 of 18 samples were mutant, however heteroduplex bands were faint on 
the HMA both unmixed and in a 1:1 ratio with WT PCR product. Only 1 sample was visible by 
RFLP and both samples showed WT sequencing traces, suggesting mosaicism with only a small 
proportion of mutant cells (Supplementary Figure 3).   
Mutation analysis of 36 AsCpf1/gRNA injected embryos revealed a mutation rate of 33%.  
Results were consistent across unmixed and WT mixed HMA assays and RFLP analysis 
indicating that large deletions affecting primer binding sites did not occur (Supplementary 
Figure 4). Selected mutations were confirmed by sequencing and mixed traces observed 
following the expected cleavage site in samples with strong undigested bands in RFLP analysis 




High frequency of mono-allelic mutations using SaCas9 KKH  
Zygote injection and transfer of SaCas KKH mRNA/gRNA yielded 25 embryos. Results from 
HMA (mixed and unmixed) were consistent with BsiHKAI RFLP analysis, revealing 14 mutants 
(56%, Figure 3, Supplementary Figure 5). Interestingly, almost all SaCas9 KKH mutant samples 
(13 of 14 mutant samples, 93%) appeared to have a remaining WT allele, which is rarely 
observed with WT SpCas9 injections (1 of 18 mutants- 6%, Figure 2b, Supplementary Figure 
1b). To confirm the heterozygosity (single hit), we sequenced the cloned PCR products from 
the 13 samples. Consistent with BsiHKAI RFLP analysis, all samples contained both wild type 
and mutant alleles (Supplementary Figure 6). 
While SpCas9 generates bi-allelic mutations with very high efficiency, this can be a 
disadvantage when targeting genes that cause nullizygous embryonic lethality as founder 
embryos die before birth. This problem is particularly acute when introducing a deleterious 
point mutation via HDR-mediated repair (which is less efficient than NHEJ) as the point 
mutation is almost always accompanied by a loss of function indel mutation on the other 
allele, resulting in embryonic lethality. Given the propensity of SaCas9 KKH to generate 
heterozygous indel mutations, we reasoned that we could exploit this property to generate 
mutants with an HDR-mediated mutant allele and a WT allele. To test this, we injected a ssDNA 
oligonucleotide repair template with 4 nucleotide differences encoding a BsmBI restriction site 
and “PAM killing” substitution with WT SpCas9 or SaCas9 KKH mRNAs and their cognate Ngn3 
gRNAs (Figure 4a). Embryos were collected mid-gestation for DNA extraction. BsmBI restriction 
digests of the Ngn3 PCR product revealed 6 of 27 (22%) SaCas9 KKH embryos had 




restriction site (Table 3). The presence of a WT allele in these samples was assessed by BsiHKAI 
digest, showing 6 of 6 (100%) of SaCas9 KKH samples retained a WT allele (Supplementary 
Figure 7a). Conversely, just 2 of the 4 (50%) WT SpCas9 samples with oligo insertions had a WT 
allele intact (Supplementary Figure 7b). Sanger sequencing confirmed the oligo insertion in all 
cases, showing mixed traces at the restriction sites (Figure 4b). 
SaCas9 KKH cleaves effectively at different loci 
We next wanted to confirm the capacity of SaCas9 KKH to create mutations at a different 
genomic location. To assess this, we selected the tyrosinase (Tyr) gene for targeted 
mutagenesis. Tyrosinase is essential for the production of melanin which is the pigment 
responsible for black coat colour. Cells lacking tyrosinase appear white while cells containing at 
least one functional copy are black.  Thus, Tyr provides a useful marker to identify nullizygous 
and mosaic null founders.  Mouse zygotes were injected with (300ng/uL) SaCas9 KKH mRNA 
and a gRNA targeting exon 1 and transferred to pseudopregnant females. Screening of 
founders via HMA revealed that 9 of 35 (25%) had mutations at the Tyr locus (Table 4). Of the 9 
resulting founders only 1 had phenotypic evidence of nullizygous mosaicism (patchy 
black/white coat colour, Supplementary Figure 8d) whilst the remaining 8 mutants had fully 
black coats, providing further independent evidence that SaCas9 KKH generates mostly 
heterozygous founders. Sequencing the 9 mutants confirmed indels at the SaCas9 KKH cut site, 
as well as a remaining WT allele. Finally, to confirm that mutations created by SaCas9 KKH 
could be transmitted to the next generation, 5 founders (male and female) were bred and 
offspring from one female and one male (40%) had mutations based on HMA analysis and/or 





CRISPR/Cas9 technology has enabled rapid production of genetically modified mice for 
modelling human physiology and disease. However, the limitation imposed by the NGG PAM 
requirement means that some regions of the genome remain untargetable. This is particularly 
pertinent for HDR-mediated mutagenesis where efficiency is enhanced by cleaving as close as 
possible to the site of the intended mutation 8. Whilst a number of CRISPR variants with 
different PAM recognition have become available, their ability to generate mutations in mice 
has not yet been reported. Validating these variants will extend the available toolkit for 
genome editing in mice and potentially other mammals, increasing flexibility and broadening 
the targetable regions of the genome. 
In this study, we assessed the mutagenic activity of AsCpf1, SpCas9 VQR, SpCas9 VRER and 
SaCas9 KKH CRISPR variants via mouse zygote injection, using WT SpCas9 as a “positive 
control”. All variants successfully generated mutations at the target site, although significant 
variations in efficiency were observed (Table 1). 
Previous studies have shown that injection of zygotes with AsCpf1 generated mutations in 18-
79% of offspring 21. Consistent with these data, we observed an AsCpf1 mutation rate within 
this range (33%). Notably, a recent report showed higher editing efficiency with pronuclear 
injection and high AsCpf1 mRNA concentrations, which may be a useful strategy for future 
applications 24. We have also shown for the first time that SpCas9 VQR and VRER variants are 
functional in mouse zygotes, though the mutation efficiency was lower than that of WT SpCas9 
(11% and 6%, respectively). These variants will require further testing at additional genomic 




variant was previously shown to have maximum efficiency when targeting a site with a NGAG 
PAM, with the NGAT PAM (as used in this study) being its second preferred PAM sequence 15.  
The most striking finding of this study was the activity of the previously untested SaCas9 KKH 
variant.  Mutations were detected in 25-70% of mouse embryos enabling steady generation of 
mutant founders from a single injection session. Importantly, unlike WT SpCas9, the SaCas9 
KKH variant left an intact WT allele in 93% of mutant embryos. Furthermore, when introducing 
a point mutation via HDR, a WT allele remained in 100% of HDR edited embryos while WT 
SpCas9-injected samples had a WT allele in only 50%.  We propose that SaCas9 KKH may prove 
a useful alternative to WT SpCas9 when introducing deleterious point mutations into genes 
essential for embryonic survival.  
We showed that this feature of SaCas9 KKH was applicable to other genomic locations and 
confirmed that mutations in the tyrosinase gene induced by SaCas9 KKH were transmitted 
through the germline, making it suitable for colony generation. The lack of white coat colour in 
mutant pups provides further evidence that SaCas9 KKH does not generate mutations in both 
alleles.  This result also argues against the unlikely possibility that SaCas9 KKH generates 
mosaic mice composed of WT and homozygous mutant cells (which would be indistinguishable 
from heterozygous mice in molecular genotyping assays).  The increase of SaCas9 KKH mRNA 
concentration when injecting the tyrosinase gRNA did not increase efficiency of mutation, nor 
seem to affect the monoallelic mutagenic activity of the variant. At the higher and lower mRNA 
concentration, SaCas9 KKH showed higher transfer to offspring rates than WT SpCas9. The 




that they do not have any greater toxic effect on the zygote than the commonly used WT 
SpCas9.   
The mechanism by which the SaCas9 KKH variant fails to modify all available alleles remains 
unclear, although we hypothesize that it is simply a consequence of lower nuclease efficiency. 
While the mutagenic activity is robust, it appears that the variant is not as active as WT SpCas9, 
reducing the probability of multiple mutations. The kinetics of mRNA translation and assembly 
of the SaCas9 KKH/gRNA RNP complex may be responsible, resulting in later induction of the 
DSB. In vivo degradation of the protein, mRNA or RNP may also be more rapid, preventing 
further cleavage of the target DNA. Indeed, many of our SaCas9 KKH mutant sample 
sequencing traces showed mutant allele dosage of around 1 in 4, suggesting that mutations 
occurred after the single cell stage, resulting in mosaicism (eg. Figure 4). Mosaicism in founders 
is well established when using SpCas9 and has also been observed with mouse zygote injection 






Our results confirm the utility of a number of new variants for targeting the mouse genome by 
zygote microinjection. The novel PAM sequences of the variants tested provide more flexibility 
when designing gRNAs to target specific genetic loci; of particular importance when targeting 
for HDR insertion. We have also characterised SaCas9 KKH as a useful alternative to WT SpCas9 
when targeting point mutations into genes that cause nullizygous embryonic lethality. Further 
investigation of SaCas9 KKH mRNA and gRNA optimal concentrations is required and could 
increase its targeting efficiency or affect its tendency to edit just a single allele. Similarly, 
microinjection of ribonuclear protein (RNP) complex may result in higher efficiency of editing 
both or a single allele. A number of CRISPR variants that have been characterised in human 
cells still remain to be tested in the context of mouse genome editing, potentially enabling 
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(% of transferred) 
Mutant 
WT SpCas9 121 95 11.5-12.5 20 (21%) 18 of 19 (95%) 
AsCpf1 71 61 10.5 36 (59%) 
12 
(33%) 
SpCas9 VQR 39 35 12.5 18 (51%) 
2 
(11%) 
SpCas9 VRER 58 55 11.5-12.5 16 (29%) 
1 
(6%) 
SaCas9 KKH 65 58 10.5-11.5 25 (43%) 
14 
(56%) 
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Figure 1: Schematic of the Ngn3 intronic target site with gRNA targets and PAM sites for 
each variant beneath. Cut site for each endonuclease indicated by arrowheads 
corresponding to their colour. PvuII (purple) and BsiHKAI (green) restriction endonuclease 
recognition sites are highlighted, and their respective cut sites marked within. PCR primer 







Figure 2: Representative results from 11.5-12.5dpt embryos following microinjection of 
WT SpCas9 and Ngn3 intron gRNA. (a) A region spanning the Ngn3 target site was PCR 
amplified and reannealed. Heteroduplex formation was assessed by polyacrylamide gel 
electrophoresis. (b) PCR products mixed with WT PCR product before annealing, then run 
on polyacrylamide gel. (c) Restriction digest with BsiHKAI, with no enzyme (-) and enzyme 
(+) conditions run side by side. Wild type (WT), positive control (+ve) and negative 






Figure 3: Representative results from 10.5-11.5dpt embryos following microinjection of 
WT SaCas9 KKH and Ngn3 intron gRNA. (a) A region spanning the Ngn3 target site was 
PCR amplified and reannealed. Heteroduplex formation was assessed by polyacrylamide 
gel electrophoresis. (b) PCR products mixed with WT PCR product before annealing, then 
run on a polyacrylamide gel. (c) Restriction digest with BsiHKAI, with no enzyme (-) and 
enzyme (+) conditions run side by side. Wild type (WT), positive control (+ve) and 






Figure 4: Generating a point mutation at the Ngn3 intronic site using WtSpCas9 and 
SaCas9 KKH. (a) A schematic of the Ngn3 target site, including gRNA sequences and 
endonuclease cut sites. The ssDNA oligonucleotide donor is shown above with base 
changes marked in red. The newly created BsmBI restriction site is highlighted in blue and 
existing BsiHKAI site highlighted in green. (b) Example of Sanger sequencing traces across 
the Ngn3 intron region from SaCas9 KKH (sample 11) and WTSpCas9 embryos with 
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Supplementary Material  
Supplementary Figure 1: Embryo screening results for 20 samples from 11.5-12.5dpt 
embryos following microinjection of WT SpCas9 and Ngn3 intron gRNA. (a) A region 
spanning the Ngn3 target site was PCR amplified and reannealed. Heteroduplex 
formation was assessed by polyacrylamide gel electrophoresis. (b) PCR products mixed 
with WT PCR product before annealing, then run on polyacrylamide gel. (c) Restriction 
digest with BsiHKAI, with no enzyme (-) and enzyme (+) conditions run side by side. 
Mutant samples marked with *, wild type (WT), positive control (+ve) and negative 






Supplementary Figure 2: Embryo screening results for 16 samples from 11.5-12.5dpt 
embryos following microinjection of SpCas9 VRER and Ngn3 intron gRNA. (a) A region 
spanning the Ngn3 target site was PCR amplified and reannealed. Heteroduplex 
formation was assessed by polyacrylamide gel electrophoresis. (b) PCR products mixed 
with WT PCR product before annealing, then run on polyacrylamide gel. (c) Restriction 
digest with BsiHKAI, with no enzyme (-) and enzyme (+) conditions run side by side. 
Mutant samples marked with *, wild type (WT), positive control (+ve) and negative 






Supplementary Figure 3: Embryo screening results for 18 samples from 12.5dpt embryos 
following microinjection of SpCas9 VQR and Ngn3 intron gRNA. (a) A region spanning the 
Ngn3 target site was PCR amplified and reannealed. Heteroduplex formation was 
assessed by polyacrylamide gel electrophoresis. (b) PCR products mixed with WT PCR 
product before annealing, then run on polyacrylamide gel. (c) Restriction digest with 
PvuII, with no enzyme (-) and enzyme (+) conditions run side by side. Mutant samples 






Supplementary Figure 4: Embryo screening results for 36 samples from 10.5dpt embryos 
following microinjection of AsCpf1 and Ngn3 intron crRNA. (a) A region spanning the 
Ngn3 target site was PCR amplified and reannealed. Heteroduplex formation was 
assessed by polyacrylamide gel electrophoresis. (b) PCR products mixed with WT PCR 
product before annealing, then run on polyacrylamide gel. (c) Restriction digest with 
BsiHKAI, with no enzyme (-) and enzyme (+) conditions run side by side. Mutant samples 






Supplementary Figure 5: Embryo screening results for 25 samples from 10.5-11.5dpt 
embryos following microinjection of SaCas9 KKH and Ngn3 intron gRNA. (a) A region 
spanning the Ngn3 target site was PCR amplified and reannealed. Heteroduplex 
formation was assessed by polyacrylamide gel electrophoresis. (b) PCR products mixed 
with WT PCR product before annealing, then run on polyacrylamide gel. (c) Restriction 
digest with BsiHKAI, with no enzyme (-) and enzyme (+) conditions run side by side. 
Mutant samples marked with *, wild type (WT), positive control (+ve) and negative 






Supplementary Figure 6: Sanger sequencing results from clones of all SaCas9 KKH (a) and 
WT SpCas9 (b) Ngn3 PCR products positive for a BsiHKAI restriction site in the initial 
screen. For each sample, a clone that was positive and negative for BsiHKAI was selected 
and sequenced. BsiHKAI restriction site is highlighted in green and nature of allele 





Supplementary Figure 7: BsmBI and BsiHKAI restriction digest screens for oligo insertion 
at the Ngn3 intronic site following microinjection of endonuclease, gRNA and donor 
template. 27 SaCas9 KKH (a) and WT SpCas9 (b) samples were collected at 12.5 dpt and 
PCR amplified across the Ngn3 region. Restriction digests with BsiHKAI (upper panel) and 
BsmBI (lower panel) shown, with no enzyme (-) and enzyme (+) conditions run side by 
side. Wildtype (WT), positive control (+ve) and negative controls (H2O) included. Samples 






Supplementary Figure 8: Heteroduplex screening for 35 founder samples following 
cytoplasmic microinjection of SaCas9 KKH and Tyrosinase Exon1 gRNA. (a) A region 
spanning the Tyrosinase target site was PCR amplified and reannealed. Heteroduplex 
formation was assessed by polyacrylamide gel electrophoresis. (b) PCR products mixed 
with WT PCR product before annealing, then run on polyacrylamide gel. (c) Unmixed PCR 
samples from the offspring of two founders (9 and 10) after breeding with WT C57BL/6 
females confirming germline transmission from founder #9. Wildtype (WT), positive 
control (+ve) and negative controls (H2O) included. (d) Mosaic founder #18 (indicated by 





Supplementary Figure 9: mRNA for all endonucleases used in microinjection confirming 


















Chapter 4:           
Evaluation of antibodies for 
immunofluorescent detection 
of endogenous HA-FLAG 






CRISPR/Cas9 technology has opened up countless possibilities for genome editing and 
dramatically simplified the production of genetically modified mice. Previously, creating subtle 
mutations or small sequence insertions in mice was impractical due to the time required and 
low efficiency of the gene targeting method. Now it is simple, fast and efficient. Our laboratory 
has recently used genome editing to produce the PCDH19HA-FLAG mouse, containing HA and 
FLAG small epitope tags at the C terminal end of the protein92. This mouse was produced to 
overcome our lack of specific antibody for endogenous WT PCDH19 protein.  
Protocadherin 19 (PCDH19) is an X-linked gene, meaning that one copy of the gene randomly 
undergoes X-inactivation early in development, resulting in expression of a single allele. 
PCDH19-related disease has unusual inheritance; patients with homozygous mutations in 
PCDH19 are unaffected, whilst heterozygous mutation carriers suffer from protocadherin 19 
girls clustering epilepsy (PCDH19-GCE). Through crossing the PCDH19HA-FLAG mouse with a 
transgenic PCDH19 knockout (PCDH19-Geo), we were able to stain for wild type PCDH19 cells 
with a commercial HA antibody and for knockout cells with an antibody against -
galactosidase. We described striking cell sorting defects in mice heterozygous for the PCDH19-
Geo/PCDH19HA-FLAG and not in homozygous mutants. The PCDH19HA-FLAG/+ mouse also served as a 
useful control to demonstrate normal X-inactivation for comparison to the disease-related 
abnormal cell sorting.  
Whilst localising endogenous PCDH19HA-FLAG, we noticed that many of the commercial 
antibodies trialled were not suitable for staining specifically on mouse brain. This manuscript 




their specificity. We began by overexpressing a PCDH19HA-FLAG construct in Cos cells and 
compared each antibody to an empty vector control, showing that all antibodies work on 
overexpression protein levels. We next tested the antibodies on PCDH19HA-FLAG embryonic 
brain tissue and compared to PCDH19 WT tissue. Only two antibodies (one HA and one FLAG) 
were suitable for specific staining of endogenous PCDH19HA-FLAG in vivo.  
Given that CRISPR/Cas9 technology has made the tagging of proteins fast and simple, more 
researchers are likely to use this technique to overcome a lack of specific antibody. This 
manuscript will serve as a useful guide to help researchers in their choice of epitope tag and 
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Background: Localisation of proteins in vivo is integral to the understanding of gene function 
and human disease. However, specific antibodies are often not available for the protein of 
interest, particularly when immunostaining complex tissue such as the developing mouse 
brain. The advent of CRISPR/Cas9 genome editing technology has enabled efficient 
modification of endogenous proteins with small epitope tags such as HA or FLAG facilitating 
specific detection using validated commercially-available antibodies.  
Results: In this study we compared eight commercially-available antibodies against either the 
HA or FLAG epitope for their ability to detect C-terminal endogenously-tagged PCDH19 protein 
(PCDH19HA-FLAG) in the developing brain. We first confirmed the utility of each antibody on 
overexpressed PCDH19HA-FLAG in COS cells, showing that all antibodies stained specifically under 
these conditions. We next compared them by immunostaining developing brain tissue.  While 
most antibodies showed immunofluorescence signal above background, only two (one HA and 
one FLAG) could detect the epitope tags specifically and exhibited negligible background on 
wild type tissue. 
Conclusions: We identified two commercially-available antibodies that are effective tools for 
immunofluorescence detection of endogenous tagged protein complex mouse brain tissue. We 
also identified several antibodies that are not specific under these staining conditions. These 
data will aid researchers in their design of endogenous tagged protein alleles and the selection 






Mice are widely used to investigate gene and protein function and to model human genetic 
disorders. The ability to specifically detect proteins in vivo under normal and pathological 
conditions is critical for mouse model characterisation. One method for detecting a protein of 
interest is through immunostaining using an antibody against endogenous protein. However, 
antibodies are not always available to detect a protein of interest.  Additionally, those that are 
available often generate background signal through non-specific binding to other proteins, 
particularly in a complex tissue such as the mouse brain. Alternative approaches include 
overexpression of fusion proteins with a fluorescent reporter or small epitope tag.  A 
disadvantage of this approach is that both overexpression and large protein fusions (eg. GFP) 
can alter the function and/or subcellular localisation of the protein 1.  
To overcome these limitations, mouse models expressing an endogenous fusion protein with a 
small epitope tag have been developed 2-7. Epitope tags such as haemagglutinin (HA), FLAG, 
myc, and V5, which are commonly used for protein detection in vitro, can also be used to tag 
proteins endogenously. Key advantages of this approach are that these tags can be identified 
using well-characterised commercially available antibodies and the small size of the tag is 
unlikely to affect protein function in most contexts. However, until recently, this approach was 
rarely used because targeted insertion of the tag sequence into the mouse genome using 
traditional gene targeting methods was laborious, time consuming and expensive 2, 5.  
Development of genome editing techniques, particularly CRISPR/Cas9, has enabled efficient 
targeted insertion of short sequences into the mouse genome 8. The CRISPR/Cas9 system is 




directs Cas9 to the intended genomic region via complementary base pairing across a 20-
nucleotide sequence 9-11.  In the absence of a repair template, Cas9-induced DNA cleavage is 
typically repaired by non-homologous end joining to generate small indels.  However, through 
provision of a ssDNA donor template, an alternative repair mechanism termed homology-
directed repair (HDR) can be used to insert a sequence of interest such as an epitope tag at the 
site of the DNA break.  This technique was first demonstrated in mice through insertion of a V5 
tag onto endogenous Sox2 with high efficiency 3.  
We have recently used CRISPR/Cas9 mutagenesis to generate a Pcdh19 “knock-in” (KI) mouse 
model in which the modified X-linked locus encodes a C-terminal HA-FLAG protein 12. This 
model was used to investigate the pathological mechanism of PCDH19-epilepsy in which, 
unusually, heterozygous females develop the disease whereas hemizygous males do not.  As a 
specific antibody for endogenous PCDH19 was unavailable, we used the HA-FLAG KI approach 
to label “wild type” (WT) cells expressing PCDH19. Through pairing this mouse with a PCDH19 
knockout (KO) strain expressing a LacZ reporter cassette, we demonstrated dramatic cell 
sorting differences in genotypes that replicate the human disease pattern (i.e. heterozygous 
for PCDH19 KO allele). While optimising immunofluorescence experiments on this mouse, we 
tested a range of commercially available HA and FLAG antibodies with variable results. 
Given that CRISPR/Cas9 technology has made the production of endogenously tagged mice 
quick and highly efficient, it is likely that many groups will adopt a similar approach 4. 
Currently, there is a paucity of data to inform the choice of epitope or antibody for in vivo 
tagging of endogenous proteins 13, 14. Here we compared the efficacy of several commercially 




eight antibodies tested, we identified two that enabled robust specific detection of 







PCDH19HA-FLAG mice were generated using CRISPR/Cas9 as previously described12. The HA-FLAG 
sequence (TACCCATACGATGTTCCAGATTACGCTGACTACAAAGACGATGACGACAAG encoding 
YPYDVPDYADYKDDDDK) is inserted immediately 5’ of the Pcdh19 stop codon. All animal work 
was conducted in accordance with institutional and national guidelines for the use of animals 
for scientific purposes following approval by the University of Adelaide animal ethics 
committee (approval number S-2013-187). 
Cell culture and transfections 
PCDH19HA-FLAG-GFP plasmid was prepared by subcloning the mouse PCDH19 cDNA into the 
pIRES2.eGFP plasmid. The GFP-only plasmid is “empty” pIRES2.eGFP. Cos-1 cells (ATCC, CRL-
1650) were grown in 24-well trays on glass coverslips in DMEM supplemented with 10% FCS 
and 1% glutamax. Cells were transfected with 0.5ug plasmid and 1.5uL 1mg/ml 
polyethylenimine (PEI; Sigma) and cultured for 48hrs. Cells were washed with PBS, fixed with 
4% PFA/PBS and washed 3 times in PBS before blocking.  
Immunofluorescence 
Pregnant female mice were perfused with 4% PFA/PBS, embryos were harvested and their 
brains subsequently removed, postfixed for a further 4 hours, cryoprotected in 30% sucrose, 
and embedded in OCT medium. Sections (12 μm) were prepared using a Leica CM1900 
cryostat. Sections were permeabilised with PBS/0.3% Triton X-100 for 10 minutes. Blocking in 




incubation at 4°C in the same solution containing diluted primary antibody. Anti-Nestin 
antibody (Abcam ab82375) was used as a positive control. Sections or coverslips were washed 
3 times for 10 minutes in PBS and incubated in diluted secondary antibody at room 
temperature for 3 hours. After washing 3 times for 10 minutes each in PBS, slides were 
mounted in Prolong Gold Antifade plus DAPI (Molecular Probes, Invitrogen) and imaged using a 
Nikon Eclipse Ti microscope and Nikon Digital Sight DS-Qi1 camera. Antibodies and 
corresponding dilution are summarised in Table 1.  
Statistical Analysis 
Quantification of COS cell staining intensity was performed by selecting all cells positive for 
GFP, then analysing the mean TxRed intensity for GFP-only and PCDH19HA-FLAGGFP conditions 
using NIS Elements Software. Unpaired T-tests were performed between empty and tag for 
each antibody using GraphPad Prism 7 software, providing p-values. Intensities were 
normalized for graphical purposes by dividing each PCDH19HA-FLAGGFP intensity value by the 






To compare the efficacy of antibodies to detect epitope-tagged endogenous protein in brain 
tissue, we selected five commercially available antibodies that recognise the HA tag (amino 
acid sequence: YPYDVPDYA) and three that bind the FLAG tag (DYKDDDDK), generated from a 
variety of species (Table 1). To confirm the immunoreactivity of each antibody, we transfected 
COS cells with a mPCDH19HA-FLAG-GFP bicistronic expression plasmid.  Negative controls were 
transfected with CMV-IRES-GFP (GFP only). Antibodies were initially trialled at a uniform 
dilution (1:300), unless the supplier recommended lesser dilution. Two antibodies showed high 
levels of background staining at 1:300 so were diluted to 1:3000 where they showed specific 
signal (data not shown). Immunostaining on COS cells confirmed all eight antibodies bound the 
HA or FLAG epitope (Figure 1a). For each antibody, staining was quantified by selecting GFP 
positive cells, quantifying TxRed fluorescence, then normalizing the tag condition to the empty 
vector control. All antibodies exceeded a mean 2.5 fold intensity difference, with p values 
<0.0001 (Figure 1b). 
Given that all antibodies could detect overexpressed tagged PCDH19, we next tested their 
ability to detect endogenous PCDH19HA-FLAG in embryonic brains. To confirm the 
immunocompetency of the brain tissue, we used an antibody against the intermediate 
filament protein Nestin, which is expressed by radial glia in the developing brain. All samples 
that were subsequently used for anti-tag immunostaining (n=3 PCDH19HA-FLAG, n=3 wild type) 
displayed robust Nestin immunoreactivity (Supplementary Figure 2). Next, CNS tissue from 
13.5dpc PCDH19HA-FLAG and wild type were immunostained using the same antibody dilutions 
that were optimised in COS cells (Table 1). All anti-tag antibodies showed increased staining in 




staining on wild type tissue (Figure 2). Secondary-only controls confirmed no background 
staining from goat, rabbit and chicken secondary antibodies though background was evident 
with mouse secondary (Table 2, Supplementary Figure 3). Each antibody was scored across 
three biological repeats for its ability to stain specifically in addition to the extent of 
background staining (Table 2). 
Interestingly, only two of the eight antibodies generated a robust signal in PCDH19HA-FLAG 
sections with little to no background on wild type tissue. These antibodies displayed similar 
staining patterns throughout the developing cortex, further confirming specificity. The most 
effective was HA3 rabbit antibody, which stained specifically across a coronal section of the 
13.5dpc developing brain. The FLAG 6 goat antibody also proved useful for staining 
endogenous FLAG-tagged protein (Figure 3b). Together these data indicate that (i) several 
commercially available anti-tag antibodies appear unsuitable for endogenous protein detection 
applications and (ii) HA-FLAG epitope tagged protein can be detected with specific antibodies 






The inability to detect endogenous proteins is a vexed issue for many researchers.  Genome 
editing technologies have greatly simplified the generation of mice with small epitope tags on 
a protein of interest, helping to overcome this issue. These advances include the recently 
reported “SLENDR” technique that utilises CRISPR/Cas9 mediated HDR to insert a HA or FLAG 
tag, resulting in high-resolution and multiplexed mapping of protein localisation in vivo4. 
Others have used zinc finger nuclease (ZFN) or TALEN genome editing techniques to insert HA 
tags onto endogenous mouse genes and assess protein expression in either embryos or brain 
tissue6, 7. A significant issue with endogenous tagging is that it relies heavily upon the 
availability of antibodies that bind specifically to the epitope tag. Our experience with the 
PCDH19HA-FLAG mouse demonstrated that many commercially available antibodies for HA and 
FLAG epitope tags are not suitable for staining endogenous tagged protein on mouse tissue12. 
In this study, we compared HA and FLAG antibodies for their ability to specifically detect 
PCDH19HA-FLAG both overexpressed in COS cells and at endogenous levels in mouse embryonic 
brain tissue. All antibodies were effective at staining overexpressed PCDH19HA-FLAG in COS cells, 
with mean staining intensity ranging from 2.5-13.5-fold over negative controls, confirming 
their expected immunoreactivity. Many of these antibodies have been used extensively in vitro 
and are also tested in an overexpression context by suppliers. 
However, when we examined the antibodies on tagged PCDH19 at endogenous levels in 
embryonic brain tissue, many antibodies did not perform effectively. Aside from HA3 and 
FLAG6, all remaining antibodies displayed significant background staining in vivo. At the 




can be attributed partly to cross-reactivity of secondary antibody (as evidenced in secondary-
only controls, Supplementary Figure 3). The remaining three antibodies (HA2, HA4 and FLAG8) 
also showed non-specific staining on wild type tissue despite secondary only controls showing 
no staining on the same tissue.  
HA3 and FLAG6 antibodies proved to be the most useful for detecting the PCDH19HA-FLAG 
protein on mouse embryonic tissue. Though slight cross-reactivity occurred on wild type tissue, 
particularly for FLAG6, both provide specific staining patterns consistent with Pcdh19 
expression in the developing brain without producing significant background staining. HA3, 
along with HA5 and FLAG8 have been used effectively for immunofluorescence on mouse brain 
tissue with single cells containing endogenous epitope tagged protein, though with HA3 and 
HA5 at slightly higher dilutions (1:1000) 4. 
Whilst the comparison shown here provides two antibodies that provide robust detection of 
endogenous HA or FLAG epitopes, many factors can influence the success of 
immunofluorescence, making the choice of antibody (and epitope tag) for in vivo endogenous 
tagging experiments a complex one. Antibody performance will undoubtedly vary depending 
on the expression level of the endogenous protein of interest, the location/accessibility of the 
epitope tag and the tissue type analysed. It is also possible that further optimisation of staining 
conditions including antibody dilution for those that showed background on wild type tissue 
may improve their signal to noise ratio. 
Our work and that of and others clearly demonstrates the utility of epitope tags for visualizing 
a protein of interest in vivo 4, 12. Here, we compared a series of commercial antibodies for their 




FLAG (FLAG6) antibody were effective in the context of the PCDH19HA-FLAG mouse brain. The 
staining comparison presented here provides a simple reference guide for researchers 
undertaking similar experiments and provides not just two candidate antibodies, but a logical 
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2367 1:100 1:100 







3724 1:1600 1:300 
HA4 Abcam Chicken Polyclonal ab9111 Not provided 1:300 
HA5 Covance Mouse 
Monoclonal 
HA.11 
MMA-101R 1:1000 1:300 
FLAG6 Abcam Goat Polyclonal ab1257 1:200-1:2000 1:3000 
FLAG7 Sigma Mouse 
Monoclonal 
M2 
F3165 1:200 1:200 
FLAG8 Sigma Rabbit Polyclonal F7425 1:100 1:3000 














HA1 **** ++++ +++ 
HA2 **** +++ + 
HA3 **** - - 
HA4 **** ++ - 
HA5 **** +++ +++ 
FLAG6 **** + + 
FLAG7 **** +++ ++ 
FLAG8 ** ++ + 
Table 2: Summary of staining pattern on tissue for antibodies tested. 
Key:  ****  very specific  - no background 
 ** less specific  + low background 
     ++ medium background 
     +++ high background 






Figure 1: Immunofluorescent staining on COS cells transfected with CMV-PCDH19HA-FLAG or 
empty vector. a) Example of COS cell stains demonstrating strong staining in PCHD19HA-FLAG 
conditions and not in empty vector controls. Corresponding GFP fluorescence 
demonstrates transfected cells. b) Quantification of COS cell stains for fold TxRed intensity 








Figure 2: Comparison of immunofluorescence on mouse cortex from PCDH19HA-FLAG and 
wild type mice using HA and FLAG commercial antibodies. Brain tissue from 13.5dpc 






Figure 3: Immunofluorescence on mouse cortex from PCDH19HA-FLAG and wild type mice 
demonstrating specific staining by HA3 and FLAG6 commercial antibodies. Brain tissue 
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Supplementary Figure 1: Immunofluorescent staining on Cos cells transfected with CMV-
PCDH19HA-FLAG or empty vector using each of the selected commercial antibodies. GFP 





Supplementary Figure 2: Immunofluorescent staining using Nestin antibody on tissue 





Supplementary Figure 3: Immunofluorescence on mouse cortex from PCDH19HA-FLAG and 
wild type mice using HA and FLAG commercial antibodies, including secondary only 

















Chapter 5:          





5.1 Paroxysmal phenotypes in Prrt2 mouse models  
In Chapter 2 we described a series of phenotypes in the Prrt2 KO mouse that reflect diseases 
observed in patients with mutations in PRRT2. Most notably, we observed spontaneous 
paroxysms and unexplained death in Prrt2 KO animals, with deaths also occurring in a small 
number of HET animals. The vast majority of patients with PRRT2-related disorders have 
heterozygous mutations in PRRT2, with only a few reported homozygous patients, who 
experience increased severity of the same episodic phenotypes. While the HET mice in our 
study did not display spontaneous paroxysms, our stronger KO phenotype reflects the 
increased severity seen in homozygous patients. Recent studies on mice lacking Prrt2 support 
this, with Michetti et al. observing audiogenic paroxysms in KO animals only, and Tan et al. 
describing induced dyskinesia in all homozygous Prrt2STOP animals and in fewer 
heterozygotes27, 33.  
Our study extends the series of behavioural abnormalities in Prrt2 mice that reflect the 
spectrum of diseases observed in patients. Table 5.1.1 summarises the tests that displayed 
differences in HET or KO animals, comparing the outcomes of these across studies. Whilst our 
behavioural testing results remain relatively consistent with the Michetti et al. investigation of 
the Prrt2 KO mouse, Tan et al. describe deficits in rotarod performance and shorter latency to 
PTZ-induced seizure that were not observed in the other two studies. The models are 
maintained on different C57Bl/6 substrains that are known to have genetic and phenotypic 
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Each of the three papers study spontaneous paroxysmal events in the mice, all of which have a 
movement disorder component. There are inherent difficulties in defining/investigating a 
spontaneous phenotype in mice, particularly one that is so infrequent. One of the clinical 
differences of PKD over an epileptic seizure is the lack of unusual EEG activity during the event, 
however the rarity of the events makes EEG analysis impractical. We instead rely on events 
observed/captured by chance and subsequent interpretations of the behavioural 
manifestation. A similar problem comes to the fore with the unexpected death phenotype we 
observed in Prrt2 KO mice. The age of death was variable, and deaths occurred in less than 
10% of mice, making monitoring for events difficult. The C57BL/6N genetic background that 
our mice are maintained on is known to be relatively seizure resistant93. To obtain a stronger 
paroxysmal phenotype in mice, the Prrt2 KO allele could be backcrossed to a more seizure-
susceptible background such as DBA/2. A Prrt2 loss of function allele could also be produced 
using CRISPR/Cas9 mutagenesis with wild type DBA/2 zygotes to save the time and expense of 
backcrossing for numerous generations. If the phenotype in DBA/2 Prrt2 KO mice is more 
pronounced, it will be more straightforward to capture deaths and paroxysmal events, 
allowing better characterisation of these phenotypes.  
While sudden unexpected death in epilepsy (SUDEP) is one explanation for the premature 
death phenotype, it is also possible that Prrt2 mice experience periods of status epilepticus 
(seizure episodes lasting longer than 30 minutes) and die as a result. In humans, status 
epilepticus is considered a cause of death, excluding these instances from being classed as 
SUDEP 94. An example of another genetic mouse model that displays SUDEP is that for Dravet 
syndrome (Scn1a loss of function), in which continuous ECG recordings show altered heart 




nervous system and the heart. Given that PRRT2 was recently shown not to interact with Scn1a 
sodium channel Nav1.1 and that Prrt2 expression levels are very low/absent in the heart, it is 
likely that the cause of death differs between the two models. Neither SUDEP nor status 
epilepticus are common in patients with Prrt2 mutations, however one patient with probable 
SUDEP has been described96.  
It is still not understood how mutations in PRRT2 result in the spectrum of episodic disorders 
seen in patients, in particular, how epilepsy can occur in infancy and the distinct movement 
disorder in adulthood. As there is no apparent genotype-phenotype correlation, it has been 
suggested that the age-dependency of the disorders is due to differing levels of Prrt2 
expression over time and in different brain regions. Protein and transcript analysis have shown 
differing expression across time in the mouse brain (expression peaks at P14) and western blot 
data from Tan et al. suggests that PRRT2 may persist at higher levels into adulthood in the 
cerebellum than in whole brain16, 27. A more extensive quantitative analysis of protein 
expression across time and in specific brain regions may reveal expression changes that could 
explain why certain phenotypes predominate at different ages. This can be paired with 
phenotypic analysis of Prrt2 HET and KO mice at the same time points to determine whether 
paroxysmal phenotypes, cognitive deficits or gait abnormalities are also age-dependent.  
The Prrt2STOP mouse genetically mimics the c.649dupC frameshift mutation observed in more 
than 80% of patients, however numerous other nonsense and missense mutations have been 
linked to BFIE, PKD and ICCA. Evidence from in vitro studies on selected frameshift and 
missense mutations suggest that failure to be transported to the membrane may be a feature 




show significantly reduced protein levels suggesting this may be the cause for disease. Future 
studies could investigate the functional significance of selected missense mutations in mice. 
This could be achieved through CRISPR/Cas9 mediated knock-in of point mutations in mice and 
comparison of the resulting behavioural phenotypes to Prrt2 KO or Prrt2STOP mice. Analysis of 
protein levels for different mutants, as well as assessment of sub-cellular localisation in brain 
slices or primary neurons, would determine if mislocalisation or lowered expression is 
responsible for the pathogenicity of the mutation. It is also possible that mutant protein acts 
through a dominant negative mechanism, by binding and interfering with wild type PRRT2, 
however such interaction has not been demonstrated. Electrophysiological recordings from 
the cerebellum of missense mutant mice would reveal whether the phenotypes resulting from 
the Prrt2STOP mutation in mice are common to other Prrt2 mutations. These phenotypes 
included higher frequency miniature excitatory postsynaptic currents (mEPSCs) and increased 
synaptic facilitation.  
Recent findings around the molecular function of PRRT2 have begun to fill the gaps in 
understanding how mutations may lead to disease. Studies in PC12 cells indicate that PRRT2 
may be acting to inhibit SNARE proteins at the synapse and that its absence or mutation results 
in increases in vesicle fusion/exocytosis31. This increased release of neurotransmitters leads to 
higher neuronal excitability- a key feature of epilepsy. The inhibitory role of PRRT2 on Na+ 
channels Nav1.2 and Nav1.6 also points to how mutations in PRRT2 can lead to over-excitability 
in neurons32. If PRRT2 is mutated or absent and unable to limit Na+ channel availability on the 




The role of PRRT2 as a calcium sensor at the synapse- with loss of PRRT2 resulting in a lowered 
neurotransmitter release - may be having a separate and opposite effect on excitability. 
However, if release probability is reduced specifically in inhibitory neurons it is likely that the 
overall effect could be overexcitability. Interestingly, PRRT2 did not modulate Nav1.1 which 
predominates in inhibitory neurons, suggesting that the overexcitability may not occur in these 
neuron types, possibly compounding the imbalance of excitation/inhibition32, 97. A complex 
interplay between these functions likely contributes to the variability in paroxysmal 





5.2 Increased flexibility for mouse genome editing  
In Chapter 3, we tested new CRISPR variants with different PAM recognition for mouse 
genome editing. Whilst we showed that all variants (WT SpCas9, SpCas9 VQR, SpCas9 VRER, 
AsCpf1 and SaCas9 KKH) were capable of editing the mouse genome, some variants showed 
low editing efficiency. All endonucleases were targeted to an overlapping region in the Ngn3 
intron with the aim of reducing potential locus-specific differences in cleavage efficiency. 
However, variants will need to be tested at more genomic loci to gain a better understanding 
of mouse genome editing efficiency (especially those with lowest efficiency; VQR and VRER). 
These variants cleave efficiently in human cell lines, suggesting that the mutation rate we 
observed in mice can be improved. Lower activity may be due to sgRNA sequence-specific 
differences, or in the case of VQR, may be due to PAM recognition differences as a result of the 
flexibility in the PAM sites (recognises a NGAN PAM). The VQR variant is most effective at 
targeting NGAG PAM sites in mammalian cells, while the NGAT site (used in our screen) is the 
second preferred PAM58. Consistent with this, in Caenorhabditis elegans the VQR variant 
favoured NGAG PAM sites over NGAT or NGAA, with NGAC PAM sites being the least effective 
for eliciting mutations98. Trialling the VQR variant with its optimal PAM sequence will be useful 
to understand the overall targeting efficiency in the mouse genome.  
We have recently become aware of another form of the VQR variant that has a quadruple 
mutation (D1135V/G11218R/R1335Q/T1337R), known as the VRQR variant76. This variant has 
improved activity on NGAA, NGAC and NGAT PAM sites, when compared to VQR, making its 
PAM recognition site more accurately NGAN. This will need to be trialled for mouse genome 




The selection of endonucleases to trial in this screen was based on the PAM recognition 
sequence and its ability to expand targetable regions of the mouse genome. Validation of the 
variants that were not trialled will still be important as they may prove to have higher targeting 
efficiency and therefore be useful additions to the mouse genome editing ‘toolkit’. Some of 
these variants (eg. St1Cas9; PAM site NNAGAAW) have long PAM recognition sequences which 
have been hypothesised to reduce nuclease off-targets, another important factor to consider 
when selecting an endonuclease for genome editing99, 100.  
Unlike in vitro genome editing, the impact of off-target mutations in mice is reduced by the 
fact that mutations can be segregated away through breeding (provided they are not closely 
linked to the on-target site). However, this process can be time consuming and expensive, so 
minimisation of these events is desirable. Whilst testing variants for off-target activity was 
outside of the scope of this manuscript, it will be interesting to compare the specificity of these 
endonucleases on the mouse genome. It is conceivable that each of the available PAM variants 
can be engineered in a similar way to high fidelity SpCas9 variants (eg HF1, eSpCas9 1.1, 
HypaCas9) to reduce their off-target activity. Indeed, the VQR and VRQR variant mutations 
discussed above have been combined with the HF1 mutated residues to create high-fidelity 
PAM variants that show comparable on-target activities, though these still remain to be tested 
for genome-wide specificity76.  
When looking to introduce a point mutation or stop codon, another way to reduce off-target 
activity is using the base editor (BE3), consisting of SpCas9 nickase fused to rat cytidine 
deaminase APOBEC1 and uracil glycosylase inhibitor (UGI), which facilitates the substitution of 




does occur at similar rates. This has been shown to be highly efficient in mice, making it an 
attractive choice over HDR experiments (which often have low efficiency) if the appropriate 
base change is required102. A drawback of this technique is the requirement of a PAM 
sequence within ~3-5 bases of the desired base substitution. The engineered and naturally 
occurring CRISPR variants that are available can be used in a similar way to expand the PAM 
recognition options for precision base editing. Recently, the same group have described 
updated versions of the base editor (BE4) with higher on-target and lower off-target activity, as 
well as a new editor than can convert A-G or T-C, adding to the ever-increasing flexibility of the 
CRISPR toolkit103, 104.  Future studies will need to focus on extending editing options to allow all 
combinations of nucleotide substitution and determining whether new technologies will be 
viable options for application in the production of genetically modified mice.  
An intriguing finding of our CRISPR variant study, was the propensity of SaCas9 KKH to edit only 
one allele. We propose that this feature will be most useful when performing HDR experiments 
to insert a loss of function point mutation into a gene that causes nullizygous embryonic 
lethality. This phenomenon is likely due to a ‘sweet spot’ in the efficiency of the nuclease; high 
enough to induce mutations in sufficient offspring but low enough to prevent production of 
multiple mutations. Given this point of difference to WT SpCas9, it will be useful to compare 
the activity of WT SaCas9 under these circumstances. WT SaCas9 has been shown to edit the 
mouse genome efficiently, though the screening methods used made it unclear as to whether 
a single or both alleles were cleaved most frequently65. As the PAM sites for SaCas9 KKH and 
WT SaCas9 are similar, many SaCas9 KKH targets will have a PAM compatible with WT SaCas9, 
allowing a direct comparison of the two variants. For proof of principle, it will also be 




activity on genes in which loss of function causes embryonic lethality. Experiments on this type 
of gene were not chosen for our study as we risked missing events if lethality occurred before 
tissue collection. It would be expected that SaCas9 KKH (and perhaps also WT SaCas9) will 
allow the production of a deleterious point mutation allele in the absence of an indel on the 





5.3 Epitope tagging endogenous proteins for visualisation  
In Chapter 4 we compared a series of commercial antibodies for their effectiveness in 
detecting endogenously tagged PCDH19. We demonstrated one HA and one FLAG antibody 
that specifically stained PCDH19HA-FLAG in mouse brain tissue. The remaining six antibodies 
displayed background staining on wild type tissue that may confound localisation studies. This 
study will have broad utility in assisting researchers in their experimental design as 
CRISPR/Cas9 technology has enabled simple and affordable production of mice with 
endogenous epitope tagged proteins. 
Small epitope tags will also make in vivo immunoprecipitation experiments more 
straightforward. This technique is heavily reliant on the availability of a specific antibody for 
the endogenous protein of interest. We have used this technique effectively on the PCDH19HA-
FLAG mouse to show that PCDH19 interacts with PCDH10 and PCDH17 using a FLAG antibody in 
place of a PCDH19 antibody105. For DNA binding proteins, ChIP assays could be performed 
using commercially available antibodies against an epitope tag rather than relying on an 
antibody for the chosen protein. 
An interesting application for endogenous epitope tagging that has recently arisen is the 
SLENDR technique (single-cell labelling of endogenous proteins by CRISPR/Cas9-mediated 
homology-directed repair). CRISPR/Cas9 reagents and HDR templates containing epitope tags 
for insertion are introduced by in utero electroporation into the developing mouse brain. This 
allows visualisation of protein localisation via light microscopy and even electron microscopy 
for high resolution mapping of protein localisation, without the time-consuming process of 




cells, allowing sub-cellular mapping in sparse neurons without the issue of dense tissue and 
cell overlap interrupting visualisation. The antibodies validated in Chapter 4 will be particularly 
useful for this technique, where labelling of a specific pattern is required in mouse brain tissue.  
A point of concern when tagging a protein with an epitope tag is that the epitope may affect 
the normal function of the protein, confounding interpretations of endogenous gene function 
or abolishing activity all together. Studies have revealed altered protein structure and 
interactions as a result of small epitope tags106, 107. The HA tag also has a caspase cleavage site 
and is cleaved during apoptosis108. To overcome this issue, a recent study by Georgieva et al. 
described new epitope tags called ‘inntags’ (innocuous protein tags)109. Inntags are longer (40-
96 amino acids) than FLAG or HA epitopes (8 and 9 amino acids respectively) but, unlike FLAG 
or HA, are self-structured protein domains, overcoming the high propensity for disorder. 
Researchers showed that inntags did not cause incorrect folding or mislocalisation of proteins 
and had less effect on function than commonly used strings of six FLAG or HA tags. Specific 
mouse monoclonal antibodies were developed for these tags allowing immunofluorescence 
and immunoprecipitation. Whilst promising, the use of these tags across a more diverse range 
of experiments will determine whether they consistently show less functional impact than 
FLAG or HA tags.  
Future experiments could test these in vivo by using CRISPR technology to insert an inntag at 
the terminus of a protein of interest. Inntag length is likely to make insertion more challenging, 
however the PAM variants validated in Chapter 3 will give flexibility in where a DSB can be 




for inntags to be useful for endogenous protein localisation and investigation, the antibodies 




5.4 Concluding remarks 
The data presented in this thesis highlights the utility and flexibility of mouse models to 
investigate gene function and disease. We describe phenotypes in the Prrt2 KO mouse that 
reflect the hallmarks observed in patients, further establishing it as a model for Prrt2-related 
diseases. Chapter 3 examines new approaches for production of genetically modified mice 
using CRISPR technology. We test a series of endonuclease variants with different PAM 
recognition for their ability to create targeted mutations in mice and also uncover a new 
feature of the SaCas9 KKH variant to cleave a single allele. The final study in this thesis assesses 
the efficacy of antibodies for immunofluorescence on mice with a PCDH19 endogenous 
epitope tag, showing that not all commercially available antibodies are suitable for this 
application. 
Much of the future for mouse genome modification lies with CRISPR/Cas9 genome editing. As 
more PAM variants and altered forms become available, virtually any mutation will be possible 
at any loci, including specialised insertions such as endogenous epitope tags. Importantly, with 
the ease of production improving, a bottleneck in productivity will now move downstream to 
the phenotypic characterisation of genetically modified mouse strains; a process that can be 
slow and expensive. This, however, remains essential to fully uncover a gene’s function and 







1. Valtorta F, Benfenati F, Zara F et al. PRRT2: from Paroxysmal Disorders to Regulation of 
Synaptic Function. Trends Neurosci. 2016;39:668-679. DOI: 10.1016/j.tins.2016.08.005 
2. Komor AC, Badran AH, Liu DR. CRISPR-Based Technologies for the Manipulation of 
Eukaryotic Genomes. Cell. 2017;169:559. DOI: 10.1016/j.cell.2017.04.005 
3. Cohen J. Mice made easy. Science. 2016;354:538-542. DOI: 
10.1126/science.354.6312.538 
4. Agrotis A, Ketteler R. A new age in functional genomics using CRISPR/Cas9 in arrayed 
library screening. Front Genet. 2015;6:300. DOI: 10.3389/fgene.2015.00300 
5. Hoban MD, Bauer DE. A genome editing primer for the hematologist. Blood. 
2016;127:2525-2535. DOI: 10.1182/blood-2016-01-678151 
6. Jasin M, Rothstein R. Repair of strand breaks by homologous recombination. Cold 
Spring Harb Perspect Biol. 2013;5:a012740. DOI: 10.1101/cshperspect.a012740 
7. Hesdorffer DC, Logroscino G, Benn EK et al. Estimating risk for developing epilepsy: a 
population-based study in Rochester, Minnesota. Neurology. 2011;76:23-27. DOI: 
10.1212/WNL.0b013e318204a36a 
8. Chen T, Giri M, Xia Z et al. Genetic and epigenetic mechanisms of epilepsy: a review. 
Neuropsychiatr Dis Treat. 2017;13:1841-1859. DOI: 10.2147/NDT.S142032 
9. Thomas RH, Berkovic SF. The hidden genetics of epilepsy-a clinically important new 
paradigm. Nat Rev Neurol. 2014;10:283-292. DOI: 10.1038/nrneurol.2014.62 
10. Focus on epilepsy. Nat Neurosci. 2015;18:317. DOI: 10.1038/nn.3964 
11. Wen D, Noh KM, Goldberg AD et al. Genome editing a mouse locus encoding a variant 
histone, H3.3B, to report on its expression in live animals. Genesis. 2014;52:959-966. 
DOI: 10.1002/dvg.22827 
12. Heron SE, Dibbens LM. Role of PRRT2 in common paroxysmal neurological disorders: a 





13. Becker F, Schubert J, Striano P et al. PRRT2-related disorders: further PKD and ICCA 
cases and review of the literature. J Neurol. 2013;260:1234-1244. DOI: 10.1007/s00415-
012-6777-y 
14. Ebrahimi-Fakhari D, Saffari A, Westenberger A et al. The evolving spectrum of PRRT2-
associated paroxysmal diseases. Brain. 2015;138:3476-3495. DOI: 
10.1093/brain/awv317 
15. Bruno MK, Hallett M, Gwinn-Hardy K et al. Clinical evaluation of idiopathic paroxysmal 
kinesigenic dyskinesia: new diagnostic criteria. Neurology. 2004;63:2280-2287.  
16. Chen WJ, Lin Y, Xiong ZQ et al. Exome sequencing identifies truncating mutations in 
PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet. 2011;43:1252-1255. 
DOI: 10.1038/ng.1008 
17. Szepetowski P, Rochette J, Berquin P et al. Familial infantile convulsions and paroxysmal 
choreoathetosis: a new neurological syndrome linked to the pericentromeric region of 
human chromosome 16. Am J Hum Genet. 1997;61:889-898. DOI: 10.1086/514877 
18. Caraballo R, Pavek S, Lemainque A et al. Linkage of benign familial infantile convulsions 
to chromosome 16p12-q12 suggests allelism to the infantile convulsions and 
choreoathetosis syndrome. Am J Hum Genet. 2001;68:788-794. DOI: 10.1086/318805 
19. Heron SE, Grinton BE, Kivity S et al. PRRT2 mutations cause benign familial infantile 
epilepsy and infantile convulsions with choreoathetosis syndrome. Am J Hum Genet. 
2012;90:152-160. DOI: 10.1016/j.ajhg.2011.12.003 
20. Lee HY, Huang Y, Bruneau N et al. Mutations in the gene PRRT2 cause paroxysmal 
kinesigenic dyskinesia with infantile convulsions. Cell Rep. 2012;1:2-12. DOI: 
10.1016/j.celrep.2011.11.001 
21. Riant F, Roze E, Barbance C et al. PRRT2 mutations cause hemiplegic migraine. 
Neurology. 2012;79:2122-2124. DOI: 10.1212/WNL.0b013e3182752cb8 
22. Liu Q, Qi Z, Wan XH et al. Mutations in PRRT2 result in paroxysmal dyskinesias with 
marked variability in clinical expression. J Med Genet. 2012;49:79-82. DOI: 
10.1136/jmedgenet-2011-100653 
23. Najmabadi H, Hu H, Garshasbi M et al. Deep sequencing reveals 50 novel genes for 




24. Labate A, Tarantino P, Viri M et al. Homozygous c.649dupC mutation in PRRT2 worsens 
the BFIS/PKD phenotype with mental retardation, episodic ataxia, and absences. 
Epilepsia. 2012;53:e196-199. DOI: 10.1111/epi.12009 
25. Rossi P, Sterlini B, Castroflorio E et al. A Novel Topology of Proline-rich Transmembrane 
Protein 2 (PRRT2): hints for an intracellular function at the synapse. J Biol Chem. 
2016;291:6111-6123. DOI: 10.1074/jbc.M115.683888 
26. Valente P, Castroflorio E, Rossi P et al. PRRT2 Is a Key Component of the Ca(2+)-
Dependent Neurotransmitter Release Machinery. Cell Rep. 2016;15:117-131. DOI: 
10.1016/j.celrep.2016.03.005 
27. Tan GH, Liu YY, Wang L et al. PRRT2 deficiency induces paroxysmal kinesigenic 
dyskinesia by regulating synaptic transmission in cerebellum. Cell Res. 2017. DOI: 
10.1038/cr.2017.128 
28. Liu YT, Nian FS, Chou WJ et al. PRRT2 mutations lead to neuronal dysfunction and 
neurodevelopmental defects. Oncotarget. 2016;7:39184-39196. DOI: 
10.18632/oncotarget.9258 
29. Stelzl U, Worm U, Lalowski M et al. A human protein-protein interaction network: a 
resource for annotating the proteome. Cell. 2005;122:957-968. DOI: 
10.1016/j.cell.2005.08.029 
30. Sudhof TC. Neurotransmitter release: the last millisecond in the life of a synaptic 
vesicle. Neuron. 2013;80:675-690. DOI: 10.1016/j.neuron.2013.10.022 
31. Coleman J, Jouannot O, Ramakrishnan SK et al. PRRT2 Regulates Synaptic Fusion by 
Directly Modulating SNARE Complex Assembly. Cell Rep. 2018;22:820-831. DOI: 
10.1016/j.celrep.2017.12.056 
32. Fruscione F, Valente P, Sterlini B et al. PRRT2 controls neuronal excitability by 
negatively modulating Na+ channel 1.2/1.6 activity. Brain. 2018;141:1000-1016. DOI: 
10.1093/brain/awy051 
33. Michetti C, Castroflorio E, Marchionni I et al. The PRRT2 knockout mouse recapitulates 
the neurological diseases associated with PRRT2 mutations. Neurobiol Dis. 2017;99:66-
83. DOI: 10.1016/j.nbd.2016.12.018 
34. Simon MM, Greenaway S, White JK et al. A comparative phenotypic and genomic 





35. Rosenthal N, Brown S. The mouse ascending: perspectives for human-disease models. 
Nat Cell Biol. 2007;9:993-999. DOI: 10.1038/ncb437 
36. Palmer EE, Jarrett KE, Sachdev RK et al. Neuronal deficiency of ARV1 causes an 
autosomal recessive epileptic encephalopathy. Hum Mol Genet. 2016;25:3042-3054. 
DOI: 10.1093/hmg/ddw157 
37. Penagarikano O, Abrahams BS, Herman EI et al. Absence of CNTNAP2 leads to epilepsy, 
neuronal migration abnormalities, and core autism-related deficits. Cell. 2011;147:235-
246. DOI: 10.1016/j.cell.2011.08.040 
38. Tan HO, Reid CA, Single FN et al. Reduced cortical inhibition in a mouse model of 
familial childhood absence epilepsy. Proc Natl Acad Sci U S A. 2007;104:17536-17541. 
DOI: 10.1073/pnas.0708440104 
39. Capecchi MR. Gene targeting in mice: functional analysis of the mammalian genome for 
the twenty-first century. Nat Rev Genet. 2005;6:507-512. DOI: 10.1038/nrg1619 
40. Bradley A, Anastassiadis K, Ayadi A et al. The mammalian gene function resource: the 
International Knockout Mouse Consortium. Mamm Genome. 2012;23:580-586. DOI: 
10.1007/s00335-012-9422-2 
41. Rouet P, Smih F, Jasin M. Introduction of double-strand breaks into the genome of 
mouse cells by expression of a rare-cutting endonuclease. Mol Cell Biol. 1994;14:8096-
8106.  
42. Tsai SQ, Joung JK. Defining and improving the genome-wide specificities of CRISPR-Cas9 
nucleases. Nat Rev Genet. 2016;17:300-312. DOI: 10.1038/nrg.2016.28 
43. Carroll D. Genome engineering with zinc-finger nucleases. Genetics. 2011;188:773-782. 
DOI: 10.1534/genetics.111.131433 
44. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I 
cleavage domain. Proc Natl Acad Sci U S A. 1996;93:1156-1160.  
45. Carbery ID, Ji D, Harrington A et al. Targeted genome modification in mice using zinc-
finger nucleases. Genetics. 2010;186:451-459. DOI: 10.1534/genetics.110.117002 
46. Meyer M, de Angelis MH, Wurst W et al. Gene targeting by homologous recombination 
in mouse zygotes mediated by zinc-finger nucleases. Proc Natl Acad Sci U S A. 




47. Davies B, Davies G, Preece C et al. Site specific mutation of the Zic2 locus by 
microinjection of TALEN mRNA in mouse CD1, C3H and C57BL/6J oocytes. PLoS One. 
2013;8:e60216. DOI: 10.1371/journal.pone.0060216 
48. Barrangou R, Fremaux C, Deveau H et al. CRISPR provides acquired resistance against 
viruses in prokaryotes. Science. 2007;315:1709-1712. DOI: 10.1126/science.1138140 
49. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. 
Nat Biotechnol. 2014;32:347-355. DOI: 10.1038/nbt.2842 
50. Sternberg SH, Redding S, Jinek M et al. DNA interrogation by the CRISPR RNA-guided 
endonuclease Cas9. Nature. 2014;507:62-67. DOI: 10.1038/nature13011 
51. Jinek M, Chylinski K, Fonfara I et al. A programmable dual-RNA-guided DNA 
endonuclease in adaptive bacterial immunity. Science. 2012;337:816-821. DOI: 
10.1126/science.1225829 
52. Mali P, Yang L, Esvelt KM et al. RNA-guided human genome engineering via Cas9. 
Science. 2013;339:823-826. DOI: 10.1126/science.1232033 
53. Cong L, Ran FA, Cox D et al. Multiplex genome engineering using CRISPR/Cas systems. 
Science. 2013;339:819-823. DOI: 10.1126/science.1231143 
54. Nishimasu H, Ran FA, Hsu PD et al. Crystal structure of Cas9 in complex with guide RNA 
and target DNA. Cell. 2014;156:935-949. DOI: 10.1016/j.cell.2014.02.001 
55. Jinek M, Jiang F, Taylor DW et al. Structures of Cas9 endonucleases reveal RNA-
mediated conformational activation. Science. 2014;343:1247997. DOI: 
10.1126/science.1247997 
56. Paquet D, Kwart D, Chen A et al. Efficient introduction of specific homozygous and 
heterozygous mutations using CRISPR/Cas9. Nature. 2016;533:125-129. DOI: 
10.1038/nature17664 
57. Hirano H, Gootenberg JS, Horii T et al. Structure and Engineering of Francisella novicida 
Cas9. Cell. 2016;164:950-961. DOI: 10.1016/j.cell.2016.01.039 
58. Kleinstiver BP, Prew MS, Tsai SQ et al. Engineered CRISPR-Cas9 nucleases with altered 
PAM specificities. Nature. 2015;523:481-485. DOI: 10.1038/nature14592 
59. Ran FA, Cong L, Yan WX et al. In vivo genome editing using Staphylococcus aureus Cas9. 




60. Esvelt KM, Mali P, Braff JL et al. Orthogonal Cas9 proteins for RNA-guided gene 
regulation and editing. Nat Methods. 2013;10:1116-1121. DOI: 10.1038/nmeth.2681 
61. Zetsche B, Gootenberg JS, Abudayyeh OO et al. Cpf1 is a single RNA-guided 
endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163:759-771. DOI: 
10.1016/j.cell.2015.09.038 
62. Kleinstiver BP, Prew MS, Tsai SQ et al. Broadening the targeting range of 
Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat Biotechnol. 
2015;33:1293-1298. DOI: 10.1038/nbt.3404 
63. Kim Y, Cheong SA, Lee JG et al. Generation of knockout mice by Cpf1-mediated gene 
targeting. Nat Biotechnol. 2016;34:808-810. DOI: 10.1038/nbt.3614 
64. Hur JK, Kim K, Been KW et al. Targeted mutagenesis in mice by electroporation of Cpf1 
ribonucleoproteins. Nat Biotechnol. 2016;34:807-808. DOI: 10.1038/nbt.3596 
65. Zhang X, Liang P, Ding C et al. Efficient Production of Gene-Modified Mice using 
Staphylococcus aureus Cas9. Sci Rep. 2016;6:32565. DOI: 10.1038/srep32565 
66. Fu Y, Sander JD, Reyon D et al. Improving CRISPR-Cas nuclease specificity using 
truncated guide RNAs. Nat Biotechnol. 2014;32:279-284. DOI: 10.1038/nbt.2808 
67. Tsai SQ, Zheng Z, Nguyen NT et al. GUIDE-seq enables genome-wide profiling of off-
target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015;33:187-197. DOI: 
10.1038/nbt.3117 
68. Kim S, Kim D, Cho SW et al. Highly efficient RNA-guided genome editing in human cells 
via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014;24:1012-1019. DOI: 
10.1101/gr.171322.113 
69. Lin S, Staahl BT, Alla RK et al. Enhanced homology-directed human genome engineering 
by controlled timing of CRISPR/Cas9 delivery. Elife. 2014;3:e04766. DOI: 
10.7554/eLife.04766 
70. Mali P, Aach J, Stranges PB et al. CAS9 transcriptional activators for target specificity 
screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 
2013;31:833-838. DOI: 10.1038/nbt.2675 
71. Ran FA, Hsu PD, Lin CY et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced 




72. Tsai SQ, Wyvekens N, Khayter C et al. Dimeric CRISPR RNA-guided FokI nucleases for 
highly specific genome editing. Nat Biotechnol. 2014;32:569-576. DOI: 
10.1038/nbt.2908 
73. Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to FokI nuclease 
improves the specificity of genome modification. Nat Biotechnol. 2014;32:577-582. 
DOI: 10.1038/nbt.2909 
74. Wyvekens N, Topkar VV, Khayter C et al. Dimeric CRISPR RNA-Guided FokI-dCas9 
Nucleases Directed by Truncated gRNAs for Highly Specific Genome Editing. Hum Gene 
Ther. 2015;26:425-431. DOI: 10.1089/hum.2015.084 
75. Slaymaker IM, Gao L, Zetsche B et al. Rationally engineered Cas9 nucleases with 
improved specificity. Science. 2016;351:84-88. DOI: 10.1126/science.aad5227 
76. Kleinstiver BP, Pattanayak V, Prew MS et al. High-fidelity CRISPR-Cas9 nucleases with no 
detectable genome-wide off-target effects. Nature. 2016;529:490-495. DOI: 
10.1038/nature16526 
77. Chen JS, Dagdas YS, Kleinstiver BP et al. Enhanced proofreading governs CRISPR-Cas9 
targeting accuracy. Nature. 2017. DOI: 10.1038/nature24268 
78. Davis AJ, Chen DJ. DNA double strand break repair via non-homologous end-joining. 
Transl Cancer Res. 2013;2:130-143. DOI: 10.3978/j.issn.2218-676X.2013.04.02 
79. Deriano L, Roth DB. Modernizing the nonhomologous end-joining repertoire: 
alternative and classical NHEJ share the stage. Annu Rev Genet. 2013;47:433-455. DOI: 
10.1146/annurev-genet-110711-155540 
80. Betermier M, Bertrand P, Lopez BS. Is non-homologous end-joining really an inherently 
error-prone process? PLoS Genet. 2014;10:e1004086. DOI: 
10.1371/journal.pgen.1004086 
81. Decottignies A. Alternative end-joining mechanisms: a historical perspective. Front 
Genet. 2013;4:48. DOI: 10.3389/fgene.2013.00048 
82. Shen B, Zhang J, Wu H et al. Generation of gene-modified mice via Cas9/RNA-mediated 
gene targeting. Cell Res. 2013;23:720-723. DOI: 10.1038/cr.2013.46 
83. Singh P, Schimenti JC, Bolcun-Filas E. A mouse geneticist's practical guide to CRISPR 




84. Wang H, Yang H, Shivalila CS et al. One-step generation of mice carrying mutations in 
multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153:910-918. 
DOI: 10.1016/j.cell.2013.04.025 
85. Fujii W, Kawasaki K, Sugiura K et al. Efficient generation of large-scale genome-modified 
mice using gRNA and CAS9 endonuclease. Nucleic Acids Res. 2013;41:e187. DOI: 
10.1093/nar/gkt772 
86. Zhang L, Jia R, Palange NJ et al. Large genomic fragment deletions and insertions in 
mouse using CRISPR/Cas9. PLoS One. 2015;10:e0120396. DOI: 
10.1371/journal.pone.0120396 
87. Birling MC, Schaeffer L, Andre P et al. Efficient and rapid generation of large genomic 
variants in rats and mice using CRISMERE. Sci Rep. 2017;7:43331. DOI: 
10.1038/srep43331 
88. Yang H, Wang H, Shivalila CS et al. One-step generation of mice carrying reporter and 
conditional alleles by CRISPR/Cas-mediated genome engineering. Cell. 2013;154:1370-
1379. DOI: 10.1016/j.cell.2013.08.022 
89. Mikuni T, Nishiyama J, Sun Y et al. High-Throughput, High-Resolution Mapping of 
Protein Localization in Mammalian Brain by In Vivo Genome Editing. Cell. 
2016;165:1803-1817. DOI: 10.1016/j.cell.2016.04.044 
90. Yang H, Wang H, Jaenisch R. Generating genetically modified mice using CRISPR/Cas-
mediated genome engineering. Nat Protoc. 2014;9:1956-1968. DOI: 
10.1038/nprot.2014.134 
91. Quadros RM, Miura H, Harms DW et al. Easi-CRISPR: a robust method for one-step 
generation of mice carrying conditional and insertion alleles using long ssDNA donors 
and CRISPR ribonucleoproteins. Genome Biol. 2017;18:92. DOI: 10.1186/s13059-017-
1220-4 
92. Pederick DT, Richards KL, Piltz SG et al. Abnormal Cell Sorting Underlies the Unique X-
Linked Inheritance of PCDH19 Epilepsy. Neuron. 2018;97:59-66 e55. DOI: 
10.1016/j.neuron.2017.12.005 
93. Deckard BS, Lieff B, Schlesinger K et al. Developmental patterns of seizure susceptibility 
in inbred strains of mice. Dev Psychobiol. 1976;9:17-24. DOI: 10.1002/dev.420090104 
94. Nashef L, So EL, Ryvlin P et al. Unifying the definitions of sudden unexpected death in 




95. Auerbach DS, Jones J, Clawson BC et al. Altered cardiac electrophysiology and SUDEP in 
a model of Dravet syndrome. PLoS One. 2013;8:e77843. DOI: 
10.1371/journal.pone.0077843 
96. Labate A, Tarantino P, Palamara G et al. Mutations in PRRT2 result in familial infantile 
seizures with heterogeneous phenotypes including febrile convulsions and probable 
SUDEP. Epilepsy Res. 2013;104:280-284. DOI: 10.1016/j.eplepsyres.2012.10.014 
97. Ogiwara I, Miyamoto H, Morita N et al. Nav1.1 localizes to axons of parvalbumin-
positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an 
Scn1a gene mutation. J Neurosci. 2007;27:5903-5914. DOI: 10.1523/jneurosci.5270-
06.2007 
98. Bell RT, Fu BX, Fire AZ. Cas9 Variants Expand the Target Repertoire in Caenorhabditis 
elegans. Genetics. 2016;202:381-388. DOI: 10.1534/genetics.115.185041 
99. Muller M, Lee CM, Gasiunas G et al. Streptococcus thermophilus CRISPR-Cas9 Systems 
Enable Specific Editing of the Human Genome. Mol Ther. 2016;24:636-644. DOI: 
10.1038/mt.2015.218 
100. Kim E, Koo T, Park SW et al. In vivo genome editing with a small Cas9 orthologue 
derived from Campylobacter jejuni. Nat Commun. 2017;8:14500. DOI: 
10.1038/ncomms14500 
101. Komor AC, Kim YB, Packer MS et al. Programmable editing of a target base in genomic 
DNA without double-stranded DNA cleavage. Nature. 2016;533:420-424. DOI: 
10.1038/nature17946 
102. Kim K, Ryu SM, Kim ST et al. Highly efficient RNA-guided base editing in mouse 
embryos. Nat Biotechnol. 2017;35:435-437. DOI: 10.1038/nbt.3816 
103. Komor AC, Zhao KT, Packer MS et al. Improved base excision repair inhibition and 
bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency 
and product purity. Sci Adv. 2017;3:eaao4774. DOI: 10.1126/sciadv.aao4774 
104. Gaudelli NM, Komor AC, Rees HA et al. Programmable base editing of A*T to G*C in 
genomic DNA without DNA cleavage. Nature. 2017. DOI: 10.1038/nature24644 
105. Pederick D, Richards K, Piltz S et al. Abnormal cell sorting underlies the unique X-linked 
inheritance of PCDH19 Epilepsy. bioRxiv. 2017. DOI: 10.1101/178822 
106. Chant A, Kraemer-Pecore CM, Watkin R et al. Attachment of a histidine tag to the 




causes a conformational change at the DNA-binding site. Protein Expr Purif. 
2005;39:152-159. DOI: 10.1016/j.pep.2004.10.017 
107. Song J, Markley JL. Cautionary tail: the presence of an N-terminal tag on dynein light-
chain Roadblock/LC7 affects its interaction with a functional partner. Protein Pept Lett. 
2007;14:265-268.  
108. Schembri L, Dalibart R, Tomasello F et al. The HA tag is cleaved and loses 
immunoreactivity during apoptosis. Nat Methods. 2007;4:107-108. DOI: 
10.1038/nmeth0207-107 
109. Georgieva MV, Yahya G, Codo L et al. Inntags: small self-structured epitopes for 
innocuous protein tagging. Nat Methods. 2015;12:955-958. DOI: 10.1038/nmeth.3556 
 
